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Summary 
The precisely organized complexity of the central nervous system (CNS) requires an 
enormous number of specific cell-cell interactions, presumably mediated by a diverse 
array of membrane associated proteins. The classic cadherins are known to play essential 
roles in the maintenance of neuronal connectivity and synaptic plasticity. Three complex 
genomic loci encoding proteins of the cadherin superfamily, the ?-, ?-, and ?- clustered 
protocadherins (Pcdhs), have been hypothesized to take part in this task. Their large 
number, diverse expression pattern during neurogenesis, and partial synaptic localization 
suggest a role in synaptogenesis. The genomic architecture of the clustered Pcdhs is 
reminiscent of the immunoglobulin and T-cell receptor clusters which confer the huge 
variety of antibody molecules: within each cluster, exons encoding variable extracellular 
and transmembrane domains are alternatively spliced onto a cluster-specific conserved 
intracellular domain. Thus, Pcdhs confer molecular diversity on the cell surface, with 
conserved signaling mechanisms in the cytoplasm. 
However, the physiological role of Pcdhs as well as the reason for the diversity of 
extracellular domains and the conservation of the intracellular domain have remained 
elusive. Our goal was the elucidation of the signal transduction pathways downstream of 
?-Pcdh. To this end, we attempted to identify proteins that interact with the conserved 
intracellular domain of ?-Pcdhs (?-ICD). We purified specific polyclonal antibodies 
targeted against the ?-ICD, and used them to immunoprecipitate interacting proteins from 
mouse forebrain lysates. Mass spectrometry analysis and subsequent co-
immunoprecipitation identified novel proteins involved in signal transduction pathways 
related to cell cycle control, synaptic plasticity and memory formation. To study the role 
of ?-Pcdh intracellular signaling in vivo, we additionally established a viral gene-delivery 
system into neonatal (P0) mouse brains. This method enabled us to efficiently 
overexpress the ?-ICD, which allowed us to study the intracellular signaling of ?-Pcdhs. 
Using this system we uncovered novel physiological effects of ?-ICD overexpression in 
inhibitory synapses of the cortex, with possible implications for synaptic transmission 
and plasticity. 
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Zusammenfassung  
Für die exakten Verschaltungen im zentralen Nervensystem, die wahrscheinlich durch 
unterschiedlichste membranassoziierte Proteine bestimmt werden, sind sehr viele 
spezifische Zellinteraktionen notwendig. Klassische Cadherine sind dabei nicht nur für 
die Integrität der neuronalen Vernetzung, sondern auch für synaptische Plastizität 
essenziell. Eine Unterklasse der Cadherine, die auf drei komplexen genomischen Loci 
geclusterten ?-, ?-, und ?-Protocadherine, sind wahrscheinlich auch daran beteiligt. 
Insbesondere ihre hohe Anzahl, ihr unterschiedliches Expressionsmuster während der 
Neurogenese und ihre synaptische Verankerung legen die Vermutung auf wichtige 
Funktionen während der Synaptogenese nahe. Die genomische Anordnung dieser 
geclusterten Protocadherine erinnert strukturell stark an Immunglobulin und T-Zell 
Rezeptor Gen-Cluster, welche für die enorme Vielfalt von Antikörpervarianten 
verantwortlich sind. Dabei werden unterschiedliche Cluster-spezifische Exone, welche 
die Extrazelluläre- und Transmembrandomäne kodieren, an Exone für eine einheitliche 
intrazelluläre Domäne gespleisst. Geclusterte Protocadherine vernetzen daher die 
molekulare Vielfalt an der Zelloberfläche mit einheitlichen zytoplasmatischen 
Signalwegen. Leider sind bis heute weder physiologische Relevanz noch Grund dieser 
extrazellulären Vielfalt in Verbindung mit einheitlichen intrazellulären Signalwegen 
bekannt. Ziel der vorliegenden Arbeit war die Beschreibung intrazellulärer Signalwege 
von ?-Protocadherinen. Zuerst identifizierten wir Proteine, welche an die ?-Protocadherin 
spezifische intrazelluläre Domäne (?-ICD) binden. Dazu reinigten wir polyklonale 
Antikörper gegen die ?-ICD und immunpräzipitierten damit Bindungspartner aus 
Maushirnlysaten. Mit Hilfe von massenspektrometrischen Analysen, gefolgt von Co-
Immunpräzipitationen, konnten wir neue Interaktionspartner mit bereits bekannten 
Funktionen während synaptischer Plastizität finden. Um intrazelluläre Signalwege von ?-
Protocadherinen und deren Interaktionspartnern in vivo besser zu verstehen, etablierten 
wir eine Methode zum Virus-vermittelten Gentransfer in neugeborene Mäuse. Diese 
Methode ermöglichte die Überexpression der ?-ICD, sowie die erste 
elektrophysiologische Beschreibung ?-Protocadherin induzierter Effekte an 
inhibitorischen Synapsen im Kortex.  
Introduction 
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1. Introduction 
The human brain is the most complex structure known to us, with about 1012 neurons, 
forming 1015 connections (Kandel et al., 2000). 
In comparison to these staggering numbers, the amount of genetic information encoded 
by our DNA is surprisingly small. Several biological mechanisms allow to establish this 
intricate brain circuitry. These include combinatorial use of multiple guidance cues, and 
the refinement of connections based on the correlated firing activity of neurons. 
Epigenetic modifications also contribute to phenotypic hard-wiring at the cellular level 
(Schmucker and Flanagan, 2004; Sweatt, 2009). 
When searching for the main constituents contributing, at least partially, to the 
establishment of the overwhelming specific wiring of the brain, attention is drawn to the 
large superfamily of the cadherins (Kohmura et al., 1998), and within this family, to 
clustered  Protocadherins (Pcdhs) (Lefebvre et al., 2008).  
In the following section I will detail several properties supporting the role of cadherins, 
and more specifically, ?-Protocadherins (?-Pcdhs), in forming the basic wiring diagram of 
the brain. 
 
1.1 The cadherin superfamily 
The cadherin superfamily of proteins includes more than 100 members, almost all of 
which are transmembrane proteins.  In general, cadherins are glycoproteins which 
function in calcium-dependent, selective cell-cell interactions (Wu and Maniatis, 1999, 
and references therein: Takeichi, 1991, 1995; Marrs and Nelson, 1996).  The cadherins 
contain extracellular cadherin ectodomains (ECs) in different numbers, a single 
transmembrane and a cytoplasmic domain (Takeichi, 1990; Uemura, 1998). Classic 
cadherins display a homophilic binding interface embedded within the first (N-terminal) 
EC1 domain (Morishita and Yagi, 2007). 
Cadherins can be further divided into several sub-families: the classic cadherins, 
desmosomal cadherins, protocadherins, Flamingo/CELSRs and FAT, serving different 
biological functions (Tepass et al., 2000; Redies et al., 2005). Classic and desmosomal 
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cadherins, for example, are cell adhesion proteins, but most other sub-families do not 
display strong adhesion properties, and are therefore probably more important for signal 
transduction (Takeichi, 2007). Indeed, cell adhesion and signal transduction are closely 
linked, as classic signal transduction molecules such as Notch-delta, neuroligin-neurexin, 
and Eph-ephrin, can also promote cell adhesion (Nguyen and Sudhof, 1997; Ahimou et 
al., 2004; Sela-Donenfeld and Wilkinson, 2005). 
 
1.2 Protocadherins 
Protocadherins (Pcdhs) are the largest family of proteins within the cadherin superfamily.  
More than 70 different Pcdh genes have been identified (Morishita and Yagi, 2007). The 
term Pcdhs was coined after the way these proteins were identified, by PCR with 
degenerate primers, targeted against cadherin ectodomains. Pcdhs were isolated from a 
wide range of vertebrates and invertebrates, which suggested an early primordial cadherin 
motif, a “proto” cadherin (Sano et al., 1993). 
The Pcdh family includes clustered and non-clustered Pcdhs (Redies et al., 2005). 
Clustered Pcdhs comprise the larger family, with over 50 identified members.  Three 
families of clustered Pcdhs have been identified:  the ?, ? and ? Pcdhs (designated ?-, ?- 
and ?-Pcdhs). The genes for these proteins are arrayed in tandem on a single chromosome 
(human chromosome 5 and mouse chromosome 18 (Wu and Maniatis, 1999). The overall 
genomic organization of Pcdhs is conserved in all vertebrates, however, they are not 
found in invertebrates (Noonan et al., 2004). The murine gene locus encoding ?-Pcdhs 
comprises 14 variable exons, each of which is spliced to three ?-cluster specific constant 
exons. The ?-Pcdh cluster encodes 22 different variable exons, similarly spliced to three 
?-cluster specific constant exons (Tasic et al., 2002; Wang et al., 2002a). Each of the 
different variable exons harbors its own promoter and encodes the extracellular domain, 
transmembrane domain and a short portion of the intracellular domain (Tasic et al., 
2002). The three constant exons of either ?-, or ?-Pcdhs encode the constant intracellular 
domain of the protein. In contrast, the ?-Pcdhs are encoded by 22 variable exons, lacking 
constant exons (Figure 1). The most striking feature of Pcdh organization is the similarity 
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with the immune system genes. Both the nervous system and the immune system are 
composed of enormously diversified cell types and undergo massive apoptosis, and the 
genes for the Pcdh family, as the genes for the Ig and T-cell receptor of the immune 
system are arranged in tandem arrays (Wu et al., 2001; Yagi, 2003).  However, genomic 
rearrangement was not shown for the Pcdh gene cluster, as for the genes of the immune 
system. What was seen, though, for Pcdhs, is an increased mutagenesis rate during 
embryonic development which does suggest a possible role for somatic mutations in 
increasing variability of the Pcdh genes (Hirayama et al., 2001). 
 
 
Figure 1. Clustered Pcdhs – genomic organization 
The mouse gene cluster arrangement for the ?-, ?-, and ?-Pcdhs.  Rounded squares display the different 
variable exons (?-V, ?-V, ?-V) as arrayed on chromosome 18.  Edged squares indicate the constant exons 
(?-C, ?-C) encoding the ICD (lacking in the ?-Pcdh gene cluster).  Scale bar is 10 kilobasepairs (kb). 
 
The fact that functional ?- and ?-Pcdhs result from the combination of distinct 
extracellular domains spliced to a common cytoplasmic domain suggests a mechanism in 
which distinct recognition events promote a common cellular response. Interestingly, 
structural differences between classic cadherins and Pcdhs support a role in signal 
transduction (vs. cell adhesion) for Pcdhs. Pcdhs lack the classic homodimerization motif, 
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resulting in weaker cell-adhesion capabilities. Thus, it has been suggested that Pcdhs may 
be more important in signal transduction than in cell adhesion (Morishita and Yagi, 2007, 
and references therein: Mutoh et al., 2004; Morishita et al., 2006). 
 
1.3 Expression pattern of clustered Pcdhs in the brain  
The unusual genomic organization of clustered Pcdhs raises the question of how these 
genes are differentially expressed in and during brain development.  The mode of Pcdh 
expression is complex. In cerebellar Purkinje cells, single-cell RT-PCR analysis showed 
that individual cells express different numbers of ?-Pcdh isoforms, all stemming from 
alternative splicing in a monoallelic fashion (Esumi et al., 2005).  Interestingly, within the 
22 ?-Pcdh variable genes, the ?-Pcdh A and B gene clusters share a similar mechanism of 
combinatorial monoallelic expression, but the C types are expressed in a bi-allelic fashion 
(Kaneko et al., 2006).  
Frank et al. (2005), showed expression of ?-Pcdhs in the entire brain. The strongest 
expression was detected in cerebellum, hippocampus and olfactory bulb, but ?-Pcdhs 
were also detected in cortex, mid- and hindbrain, brainstem and spinal cord.  Expression 
in general was highest in young post-natal animals (P1-3), and higher in young compared 
to adult animals (>P42).   
Each of the different isoforms of ?-Pcdhs was detected in all brain regions.  Interestingly, 
within regions, individual neurons displayed distinct ?-Pcdhs isoforms (Frank et al., 
2005). A similar expression pattern was also shown for ?-Pcdhs (Kohmura et al., 1998). 
These data strongly suggest a combinatorial monoallelic expression for Pcdhs in 
individual neurons. 
On the sub-cellular level, Pcdhs are partially localized to synapses.  In cultures, 
interneurons showed non-synaptic localization, in pyramidal neurons Pcdhs partially 
localized to synapses (Phillips et al., 2003). ?-Pcdhs are also found in biochemical 
fractions enriched in pre-synaptic proteins (“pre-synaptic web”; Phillips et al., 2001). 
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In conclusion, several properties of the Pcdhs make them good candidates for being 
involved in the task of wiring the brain. First, Pcdhs have a clustered genomic 
organization. This organization is similar to that of T-cell and B-cell receptors in the 
immune system, which provides a large variety of cell clones.  Second, the combination 
of multiple extracellular domains with an invariant intracellular signaling domain, 
allowing to couple extracellular signals with a common intracellular signal.  Third, 
expression predominantly in the CNS, and fourth, an association with synaptic 
membranes.  
 
1.4 Post-translational processing of clustered Pcdhs 
Pcdhs are type I transmembrane molecules and undergo sequential cleavage in the plasma 
membrane similar to other proteins such as Notch and APP (Schroeter et al., 1998; Ling 
et al., 2003). As a first step, the extracellular domain of the protein is released into the 
matrix by cleavage of the matrix metallo-protease ADAM10 (Reiss et al., 2006; Bonn et 
al., 2007).  Consequently, in a second cleavage step, the ?-Secretase complex processes 
the protein within the plasma membrane, releasing the intracellular domain into the 
cytoplasm. The invariant, intracellular domain (ICD) is fastly degraded by the 
proteasome, as proteasome inhibitors cause accumulation of this fragment (Haas et al., 
2005; Hambsch et al., 2005, Figure 2). The cleaved, soluble cytoplasmic domain of ?-
Pcdhs has been shown to translocate to the nucleus where it may adopt signaling 
functions. Similar processing has recently been shown in our lab for ?-Pcdhs (Bonn et 
al., 2007).  The fate of the ?-ICD is of critical importance, as it is the intracellular 
signaling molecule shared by all ?-Pcdhs.   
Introduction 
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Figure 2. Intramembrane proteolysis of ?-Pcdhs 
Schematic of ?-Pcdh protein in the plasma membrane prior to (left) and following (right) proteolytic 
cleavage by ADAM10 and ?-Secretase.  The six EC domains are released into the extracellular matrix (red 
cylinders), whereas the ?-ICD (red clinder) translocates into the nucleus (arrow) where it transactivates 
endogenous ?-Pcdhs (black bent line, nuclear membrane; red rectangles, ?-Pcdh variable region exons; 
arrows in front of exons indicate individual ?-Pcdh promoter regions). 
 
Signal transduction events, and possibly even transcriptional control, are likely mediated 
by the ICD and its interaction partners.  One main fact that supports this hypothesis is the 
presence of a nuclear localization signal (NLS) in the ICD. Indeed, when ?- or ?-ICD 
degradation is blocked by proteasome inhibitors, the ICD can be detected by 
immunostaining in the nucleus. Furthermore, luciferase assays showed transactivation of 
?-Pcdh promoters upon overexpression of the ?-ICD (Hambsch et al., 2005; Bonn et al., 
2007). 
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1.5 Transgenic mouse models for the research of ?-Pcdhs 
The importance of ?-Pcdhs is underscored by the fact that deletion of the gene locus 
(Wang et al., 2002b), or deletion of the sequence encoding the ICD (Hambsch et al., 
2005), both result in perinatal lethality. Spinal interneurons die at late stages of 
embryogenesis, causing lack of coordinated movement, and this is most likely the cause 
of perinatal death. Notably, spinal cord synapse numbers are also reduced. Other aspects 
of neurogenesis, neuronal migration, axon outgrowth and synapse formation still proceed 
in these mutants.  When neurons from mutant spinal cord were cultured, they formed 
synapses, but then died, suggesting that ?-Pcdhs are necessary for the survival of specific 
neuronal subtypes. Data from global ?-Pcdhs knock-outs are difficult to interpret as the 
two main effects are the death of spinal interneurons, and a reduction in synapse number 
in the spinal cord, either of which could be caused by the other.  It is very likely that 
death of neurons leads to a reduction in synapses connecting with other neurons.  
However, reduction of synapses may possibly occur first, leading to death of target 
neurons due to under-innervation (Wang et al., 2002b). 
In an attempt to answer this question, mice were generated, deficient for both ?-Pcdh and 
Bax (Weiner et al., 2005). Bax is a pro-apoptotic protein, and the naturally occurring 
death of many neuronal populations is greatly diminished in the Bax knock-out mouse 
(Knudson et al., 1995).  Surprisingly, although Bax deletion prevented death of spinal 
interneurons in ?-Pcdh knock-outs, it could not rescue perinatal lethality.  Notably, 
numbers of both, excitatory and inhibitory synapses were still significantly reduced (30-
50%). Similar phenotypes, including perinatal death, were seen in a hypomorphic allele 
where only part of the ICD was deleted (Weiner et al., 2005). 
These findings support the hypothesis that synapse loss and consequently neuronal death 
may be a direct consequence of ?-Pcdhs deletion.  Alternatively, Bax deletion might not 
prevent all aspects of neuronal dysfunction, as evident by the persistence of perinatal 
death.  This highlights the need for a genetic model system in which the effect of ?-Pcdh 
mutations on synapse formation and maintenance can be tested in the context of an 
otherwise healthy organism. 
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In humans, only few mutations in non-clustered Pcdhs have been described (e.g., a 
mutation in Pcdh 15 which causes Usher syndrome; Alagramam et al. (2001).  For 
clustered Pcdhs, only single nucleotide polymorphisms (SNPs) without detectable 
phenotypic consequence, and a deletion of several variable region exons of the ?-Pcdh 
cluster, also without an overt phenotype, have been described (Miki et al., 2005; Noonan 
et al., 2003).  The low number of described mutations, and the lack of any functional-loss 
mutations over such a large number of genes, points to a critical and indispensable role 
for these genes in human brain development. 
 
1.6 Recent developments in ?-Pcdhs research; the use of conditional knock-outs 
Recent studies have begun to address several of the main questions regarding ?-Pcdhs.   
Utilizing a conditional ?-Pcdh knock-out mouse in the retina, Lefebvre et al. (2008) were 
able to observe the effects of ?-Pcdhs deletion in a living mouse for several weeks, which 
was not possible in previous models (Wang et al., 2002b; Weiner et al., 2005).  This led 
to the finding that at least in the retina, ?-Pcdhs were responsible for neuronal survival. 
When a conditional retina specific ?-Pcdh knock-out mouse was crossed with a Bax 
knock-out mouse to prevent apoptosis, neurons in the retina survived and synaptogenesis 
was almost completely normal. Response to focal light stimulation was unaffected. 
Additional findings demonstrated that the time window in which ?-Pcdh activity was 
necessary is very short, as elimination of ?-Pcdhs two weeks after birth showed no 
detectable phenotypic effects. This may indicate a role for the ?-Pcdhs in the 
development, but not the maintenance, of the retina (Lefebvre et al., 2008). 
Lately, Prasad et al. (2008), have also utilized a conditional mutant, in which ?-Pcdhs 
were deleted in distinct parts of the spinal cord.  Besides showing that spinal cord 
interneurons undergo exacerbated apoptosis, they have elegantly shown that apoptosis 
was non-cell autonomous.  Migrating populations of interneurons displayed increased or 
normal levels of apoptosis, depending on the region to which they migrated. They found 
that mutant neurons did not demonstrate increased cell death, provided that they had 
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migrated into a region that expressed functional ?-Pcdhs, and wild-type cells displayed 
increased cell death in regions where ?-Pcdhs were deleted. 
Taken together, Pcdhs exert a diverse range of functions, from protection against 
apoptosis in spinal cord and retina, to regulation of synapse development. Their roles in 
the cortex, however, are not yet understood.   
 
1.7 ?-Pcdh interaction partners 
Until recently, the signal transduction pathways, which mediate Pcdh activity, were 
entirely unknown. In a recent study trying to identify interacting intracellular downstream 
molecules of ?- and ?-Pcdhs (Chen et al., 2008), the yeast two-hybrid system was utilized 
to screen for potential interaction partners.  Two interesting proteins; PYK2 and FAK, 
both tyrosine kinases, were found. Interaction of ?- and ?-Pcdhs with PYK2 and FAK 
inhibited their kinase activity, and overexpression of PYK2 could induce apoptosis in 
chicken spinal cord neurons. PYK2 activity was upregulated in ?-Pcdh deficient neurons.  
This was the first time that a signal transduction pathway has been associated with Pcdhs. 
The authors suggest that binding of PYK2 by Pcdhs would inhibit PYK2 apoptotic 
activity. Interestingly, both ?- and ?-Pcdhs could inhibit PYK2, although they have 
different conserved domains. This suggests redundancy between the clustered Pcdhs, at 
least in some aspects of their function.   
 
1.8 Virus-mediated transduction of neurons in neonatal brain 
Almost all of the data described to this date for ?-Pcdhs were obtained for spinal cord 
neurons (with the exception of the retina; Lefebvre et al., 2008). Current models for ?-
Pcdh research still lack some key features for the research of the functions of these 
proteins in higher brain functions, and new models need to be established. Mouse 
transgenic technology is currently the most reliable and well established method to study 
the functional importance of various genes in vivo. The generation of conventional 
transgenics, however, is a laborious and time consuming procedure. Preimplantation 
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embryos need to be harvested and manipulated in vitro. Transgenic animals are then 
generated by pronuclear injection of DNA into single-cell embryos. Usually tens of 
different transgenic founders have to be produced and subsequently bred with wild-type 
mice to establish a stable transgenic mouse line, expressing the transgene at sufficient 
levels and in the correct place. In many cases stochastic integration of exogenous DNA 
into the genome results in incorrect, early embryonic onset of expression, which is 
especially undesired if the exogenous gene product is likely to interfere with 
developmental processes (Capecchi, 1989a, b). 
As an alternative to classic transgenic techniques, virus-mediated transgenesis, has been 
rapidly gaining favor. Recombinant adeno–associated virus (rAAV) type 8 vectors are 
exceptionally efficient for gene transfer to the CNS, where they transduce neurons and 
mediate long-term expression of transgenes. The efficiency of rAAV8 is presumably due 
to a ubiquitous receptor conferring wide ranging tropism and rapid release of vector 
genomes into the transduced cell nucleus (Broekman et al., 2006; Burger et al., 2005; Dr. 
Matthias Klugmann, personal communication). The specificity of virus-mediated 
neuronal transgene expression can be further improved by the use of neuron specific 
promoters, restricting expression specifically to different neuronal subtypes (Kugler et al., 
2003). These unique characteristics identify rAAV8, in combination with appropriate 
promoters as a superior tool for either transducing a large neuronal population in the 
forebrain, or for systemically transducing defined brain areas, or even neuronal 
subpopulations, depending on the specific coordinates of viral injection.  
In an attempt to achieve strictly postnatal expression in the brain of mice, we developed a 
rapid, reproducible and highly versatile method for expressing transgenes. Expression is 
achieved by rAAV8 mediated transgene delivery into the neonatal mouse brain at the first 
postnatal day (P0). This can be done either globally, or in a region specific manner.  
 
1.9 Thesis objectives 
The involvement of ?-Pcdhs in intracellular signaling and apoptosis during early 
development in the spinal cord encouraged us to study ?-Pcdh signal transduction 
pathways also in the adult mouse forebrain. We decided that the most direct way to 
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address this issue would be the identification of ?-Pcdh interaction partners in the mature 
brain in vivo. 
As a first step, we immunoprecipitated ?-Pcdhs from mouse brain lysates, and used mass 
spectrometry to identify interaction partners. The interaction of various identified proteins 
was further validated by co-immunoprecipitation. Next, we managed to efficiently 
overexpress the ?-ICD, using targeted viral gene transfer in neonates. 
Electrophysiological recordings were finally used to uncover a novel phenotype of ?-ICD 
overexpression in inhibitory synapses in the cortex. 
The overexpression of the ?-ICD in the brain, as well as the putative binding proteins in 
vivo, would allow us to obtain more information about the nature of their interaction. The 
novel phenotypes and proteins we have uncovered give us our first glimpse into the role 
of ?-Pcdhs in the cortex, and allow us a way to measure the effects of genetic 
manipulations in vivo. Our results represent ongoing research aimed at the elucidation of 
the role and function of the ?-Pcdhs in the brain, and the signal transduction pathways 
through which they exert their biological function. 
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2. Materials and methods 
2.1 Antibody purification 
A CNBr Sepharose purification column (Synaptic Systems, SySy) with 1000 μl of resin 
was first washed twice with PBS by gravity flow.  Serum raised against the C-terminal 
domain of ?-Protocadherin was then loaded on the column (3-5 ml).  The column was 
then washed three times with PBS, followed by an elution of the antibody with 0.1 M 
Glycine pH 2.2.  In order to restore pH, different eluted fractions were collected in 1.5 ml 
eppendorf tubes containing 80 μl (10% elution fraction volume) or 120 μl of 1.5 M Tris 
pH 8.0.  Elution fraction volumes were 800 μl for the first, and 1200 μl for another four 
elution fractions.  Protein concentration was measured by a UV spectrophotometer at a 
wavelength of 280 nm.  Western blotting and Coomassie staining were used to confirm 
that the majority of eluted antibody was present in the second fraction, at a concentration 
of about 0.3 mg/ml. 
 
2.2 Antibody cross-linking to protein-A agarose beads 
30 μl of Protein A Agarose Fast Flow Beads (50% v/v; Sigma-Aldrich) were washed 
twice in cross-linking buffer (25 mM HEPES pH 8.2, 150 mM NaCl) by inverting the 
tubes several times and subsequently centrifuged for one minute at 2500 RPM. Tubes 
were left on ice for one minute, then buffer was removed, leaving a small volume of 
buffer to prevent bead drying. 800 μl of fresh buffer was added to the beads together with 
5 μg of the appropriate antibody (purified rabbit-anti-?-Protocadherin, non specific rabbit 
IgG (Vector Laboratories), empty beads as controls). Tubes were rotated for two hours at 
4°C to allow the antibody to bind to the beads. Excess antibody was removed and beads 
washed twice with 800 μl of fresh buffer.  In order to covalently cross-link the antibody 
to the beads, Dimethyl pimelimidate·2 HCl (DMP, Pierce Biotechnology) was dissolved 
in cross-linking buffer at a final concentration of 10 mM (freshly prepared immediately 
before use). 500 μl of the DMP solution was added to the beads and rotated for 30 
minutes at room temperature. Cross-linking reaction was terminated by addition of 200 μl 
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stopping buffer (0.5 M Tris pH 8.0), followed by 30 minutes rotation at room 
temperature. The cross-linking step was preformed twice. Beads were finally washed 
with 800 μl of 25 mM HEPES pH 7.4, 150 mM NaCl, 0.1% v/v Triton X-100. Buffer was 
removed and protein lysates added to the beads (see immunoprecipitation protocol).  For 
calibration experiments, cross-linking efficiency was assayed by dot-blot procedure. 
Rabbit IgG was cross-linked to the beads, followed by low pH elution with 150 μl of 
0.1% TFA.  Serial dilutions (1-1:27) of the eluate were made and 16 μg bovine serum 
albumin (BSA, Fermentas) was added to 4 μl of each dilution to stabilize IgGs. Finally, 5 
μl were pipetted onto a PVDF membrane.  Secondary antibody was added and ECL 
reaction carried out as described for Western blotting (section 2.4). 
 
2.3 Immunoprecipitation 
Mice were deeply anesthetized using Isofluorane (Baxter), killed by decapitation, and 
brains removed quickly into pre-chilled lysis buffer containing 25 mM HEPES pH 7.4 
and Complete™ protease inhibitor mix (Roche diagnostics GmbH). Protease inhibitors 
were not present in experiments destined for mass spetrometry analysis. 
Brains were then homogenized using a glass homogenizer (S874 Potter).  Lysates were 
incubated on ice for 10 minutes. All following steps were performed at 4°C.  Lysates 
were centrifuged for five minutes at 2000 RPM in a Biofuge table-top centrifuge to 
remove cellular debris.  Supernatant was diluted 1:2 with buffer containing 25 mM 
HEPES pH 7.4, 150 mM NaCl, and 1% v/v Triton X-100.  The lysate was then rotated for 
one hour and centrifuged for 20 minutes (13000 RPM; 20000 RCF).  Supernatant was 
precleared with 25 μl of non cross-linked Protein A agarose beads pre-washed twice with 
the same buffer, by rotating for 15 minutes.  To remove beads, lysates were centrifuged 
for another 10 minutes (13000 RPM; 20000 RCF). Supernatant was collected and is 
henceforth referred to as the Input fraction of the immunoprecipitation.  A sample was 
taken to quantify protein content with Bradford reagent (Bio-Rad Laboratories Inc.) vs. a 
standard curve of BSA (Fermentas) and read with a spectrophotometer at 595 nm 
(Pharmacia Biotech).  1.2 ml of lysate (4-5 mg/ml) were taken for immunoprecipitation, 
and mixed with 30 μl of Protein-A agarose beads cross-linked to the respective antibody.  
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Antibody-beads and protein mix were rotated overnight to allow binding. Antibodies 
used for immunoprecipitation were: purified rabbit anti-?-Pcdh, rabbit IgG (Vector 
Laboratories Inc.), mouse anti-Sam68 (Santa Cruz Biotechnology, Inc.), goat anti-SLM-2 
(Santa Cruz Biotechnology, Inc.), mouse anti-Flag (Sigma Aldrich). 
The next day, beads were separated from the lysate by centrifugation at 2100 RPM for 
one minute.  Supernatant was collected for analysis.  Beads were washed by adding 900 
μl of 25 mM HEPES pH 7.4, 150 mM NaCl, 0.1% v/v Triton X-100 followed by a one 
minute centrifugation at 2100 RPM, for 4 times.  Buffer was carefully removed each time 
with a fine gel-loading tip, leaving a small volume of buffer to prevent bead drying.  
Specifically bound proteins were eluted from the beads by addition of 120 μl of 0.2% 
trifluoroacetic acid (TFA) in double distilled water (DDW), gentle shaking at room 
temperature for 30 minutes, and centrifugation for one minute (5000 RPM).  
Immunoprecipitations destined for mass spectrometry analysis were eluted twice in 150 
μl, yielding 300 μl of total eluate fraction.  Residual protein bound to the beads was 
collected by boiling with 300 μl 3 X SDS-PAGE sample buffer.  Fractions were analyzed 
for the presence of ?-Pcdh protein by Western-blotting. 
 
2.4 Western blotting 
Protein lysates were separated by SDS-PAGE on 10% gels using standard conditions 
(Sambrook and Gething, 1989) and transferred onto PVDF membranes (0.45 μm, 
Amersham).  Reactive bands were labeled by the following primary antibodies (Abs):  
Rabbit polyclonal antiserum against ?-Pcdh (1:1000) was generated by Eurogentech 
Laboratories from purified soluble ?-ICD-10-His protein as described (Hambsch et al., 
2005), rabbit anti-GFP (1:5000, Abcam), rabbit anti-SLM-2 (1:4000, GenWay), mouse 
and rabbit anti-Sam68 (1:500, Santa Cruz Biotechnology, Inc.), mouse anti-c-Myc 
(1:500, Santa Cruz Biotechnology, Inc.), rabbit anti-Kir3.1 (1:1000, Alomone labs), 
rabbit anti-p38 (1:1000; Abcam), mouse anti-Flag (1:500, Sigma Aldrich).  After 
incubation with peroxidase-coupled anti-rabbit/mouse secondary antibodies (1:5000; 
Amersham Biosciences), the blots were incubated with chemiluminescent reagents 
(Pierce), and photographic film was exposed to produce the results. Developed films of 
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immunoblots were scanned with a flatbed scanner, and digital images were imported and 
processed by Photoshop software (Adobe).  Quantification of immunoblots was 
performed with ImageJ software (NIH). 
 
2.5 Slicing and immunostaining 
Mice were deeply anesthetized with Isofluorane (Baxter) and killed by decapitation.  
Brains were quickly removed and transferred to cold (4°C) 4% paraformaldehyde in PBS, 
pH 7.4 (PFA) and incubated overnight at 4°C.  The following day, brains were washed 
several times with PBS, and then embedded in warm Agarose in PBS (3% w/v). Agarose 
blocks were then trimmed and glued onto a stage and placed in a vibratome (Leica 
VT1000S) and immersed in PBS.  100 μm sections were sliced and brain sections 
separated from the agarose with a sharp needle.  Sections were incubated in blocking 
solution (5% normal goat serum (NGS), 1% Triton X-100, in PBS) for one hour.  Primary 
antibody was added at the appropriate concentration (rabbit anti-GFP, 1:5000, mouse 
anti-NeuN, 1:1000, Millipore; in 1% NGS, 0.5% Triton X-100, in PBS) overnight 
followed by three washes of 10 minutes with PBS.  Secondary antibody was added for 
two hours (anti-rabbit/mouse Cy-3 conjugated, 1:300 (Jackson Laboratories), or Alexa-
fluor 488 conjugated, 1:400 (Invitrogen); in 1% NGS, 0.5% Triton X-100, in PBS).  
Sections were washed for three times in PBS (10 min) and transferred to 10 mM Tris pH 
7.4 for ~5 minutes, and mounted on Superfrost plus slides (Thermo scientific) with Aqua 
Polymount (Polysciences). 
 
2.6 X-gal staining 
Vibratome sections were incubated in X-gal staining buffer (100 μl of 0.5 M K4Fe(CN)6, 
100 μl of 0.5 M K3Fe(CN)6, 100 μl of 0.2 M MgCl2, 1 ml X-Gal (20 mg/ml), and 8.7 ml 
of PBS) for 1-24 hours at 37°C.  Sections were washed 3 times in PBS for 10 minutes, 
and incubated for ~5 minutes in 10 mM Tris pH 7.4, and mounted on slides with Aqua 
Polymount (Polysciences). 
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2.7 Nissl staining 
Vibratome sections were mounted on glass-slides and incubated for 30-60 seconds in 
Nissl solution (Thionin/Lauth’s Violet, acetate salt, dissolved in 0.1M Acetic acid, 0.1M 
sodium acetate, final working concentration 0.1% w/v; Sigma-Aldrich).  Slides were 
washed three times in DDW and dehydrated by incubation for several minutes in 
increasing ethanol concentrations (70%, 95% and 100% in DDW) and finally in Xylol. 
Slides were mounted with Eukitt-quick-hardening mounting medium (Fluka). 
 
2.8 Virus purification 
Recombinant Adeno associated viruses (rAAV) were purified by discontinous Iodixanol 
density gradient centrifugation. As described in Grimm et al. (1998), except that the 
helper plasmids used, expressed the rAAV8 envelope proteins (p179 and p220, Matthias 
Klugmann, Mainz University), resulting in rAAV8 pseudotype.  Briefly, ten 15 cm HEK 
293 plates were transfected with the appropriate plasmids (5 μg of the AAV construct, 5 
μg of the p220 helper construct and 10 μg of the p179 helper construct). 48-72 hours after 
transfection cells were washed in PBS, and scraped in four ml of PBS and collected into a 
50 ml Falcon tube. Cell suspensions were centrifuged for 10 minutes in a standard tissue 
culture centrifuge (Heraus Instruments; 800 RPM, 124 G) and the pellet was resuspended 
in 9 ml of 50 mM Tris pH 8.0, 150 mM NaCl. 500 μl of NaDOC (10% w/v) and 2 μl of 
Benzonase (500 units, Sigma-Aldrich) were added and tubes were incubated for 30 
minutes at 37°C. Next, 584 mg of NaCl were added and tubes were incubated at 56°C for 
additional 30 minutes and then frozen at -70°C. Frozen cell lysates  were thawed at 37°C 
and centrifuged for 30 minutes at 7000 RPM (6000 G) in a JA20 rotor in a Beckmann 
centrifuge. The virus containing supernatant was loaded on a discontinous Iodixanol 
gradient in ultracentrifuge tubes (70 Ti) as follows: 3 ml of 54%, 3 ml of 40%, 4 ml of 
25% and 7 ml of 15% w/v. Approximately 9 ml of the cell lysate were added and 
centrifuged for 1.5 hours at 18°C in an ultracentrifuge (60000 RPM; 371,000 G). The 
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40% phase was collected with a syringe and diluted 1:2 in Magnesium and Potassium 
containing PBS (PBS-MK).  The virus solution was then concentrated in an Amicon 
Concentrator (100 kDa) 3x at 2000xG to a final volume of 500 μl and filtered through a 
0.2 mm Acrodisc filter.  10 and 20 μl samples were analyzed for viral protein amount and 
purity by SDS-PAGE. 
 
2.9 Plasmids 
?-Pcdh A1-3X Flag was generated as a PCR fragment from a template (Bonn et al., 
2007). The bidirectional promoter system and vector was described previously (Zhu et 
al., 2007).  For cloning of the ?-Pcdh A1-3X Flag into this vector instead of the Venus 
protein, the ?-Pcdh A1 was amplified by PCR, the 3’ primer containing a XhoI restriction 
site and the 3X Flag sequence (5’ primer was: 
AACATGGCGATTCCAGAGAAGTTAACC; 3’ primer was: 
CGGTCTCGAGTTACTTGTCATCGTCATCCTTGTAATCGATATCATGATCTTTAT
AATCACCGTCATGGTCTTTGTAGTCCTTCTTCTCTTTCTTGCCCGA). The PCR 
fragment was restricted with XhoI on the 3’ end. The bidirectional vector was prepared 
by restriction with BamHI and blunting with Klenow fragment, followed by restriction 
with XhoI, that released the Venus cassette and allowed the blunt-sticky (XhoI) insertion 
of the ?-Pcdh A1-3X Flag.  
For insertion instead of Cre recombinase, a PCR fragment was amplified using the same 
template and 5’ primer, and with a 3’ primer that contained the 3X Flag sequence as 
before, but with a different restriction site (ClaI: Primer sequence was 
CGGTATCGATTTACTTGTCATCGTCATCCTTGTAATCGATATCATGATCTTTAT
AATCACCGTCATGGTCTTTGTAGTCCTTCTTCTCTTTCTTGCCCGA). The vector 
was prepared in two steps, first by introduction of a ClaI restriction site containing 
oligonucleotide into the BclI site (oligonucleotide sequence was: 
GATCAATCGATTTAATTAAT), and then restriction in the EcoRV site on the 5’ side, 
and ClaI on the 3’ side, to release the Cre recombinase cassette and allow a blunt-sticky 
(ClaI) insertion of the ?-Pcdh A1-3X Flag. 
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In a third clone, ?-Pcdh A1 3X-Flag was cloned into a unidirectional rAAV vector 
encoding the human synapsin promoter fragment (Kugler et al., 2003) in two steps. First, 
oligonucleotides were designed which contained XhoI and AvrI restriction site sequences 
followed by the 3X Flag sequence (oligonucleotide sequence: 
CTCGAGCTTAAGCCTAGGGACTACAAAGACCATGACGGTGATTATAAAGATC
ATGATATCGATTACAAGGATGACGATGACAAGTAA). The vector was restricted 
with BamHI and XhoI to release a pre-existing GFP-encoding cassette, and then blunted, 
and the oligonucleotides were ligated instead (blunt-blunt insertion). In the second step, 
?-Pcdh A1 was amplified with primers containing overhangs encoding for the XhoI and 
AvrI restriction sites (5’ primer: 
TTACTCGAGACCATGGCGATTCCAGAGAAGTTAACC; 3’ primer: 
TTACCTAGGCTTCTTCTCTTTCTTGCCCGATTTC), and this PCR product was 
inserted using these sites. All cloning enzymes were purchased from Fermentas. 
 
2.10 Electrophysiological recordings of miniature synaptic currents 
Electrophysiological recordings of excitatory miniature post-synaptic currents (mEPSCs) 
in acute slices from the brains of virus-injected mice (8-9 weeks) were performed as in 
Pilpel et al. (2008) at a holding potential of -70 mV, except that 300 μm thick coronal 
slices were used. The region from which pyramidal neurons were selected (by 
morphology) corresponds to M1 motor cortex. Intracellular solution also differed and 
contained (in mM): Cs-Gluconate, 130, HEPES, 10, Phosphocreatinine, 10, Na-
Gluconate, 10, Mg-ATP, 4, Na-GFP, 0.3, EGTA, 0.2, and NaCl, 4. For the recording of 
miniature inhibitory post-synaptic currents (mIPSCs), the cells were depolarized to a 
holding potential of +10 mV (liquid junction potential was not corrected, hence this 
corresponds to the equilibrium potential for AMPA receptor channels), and outward 
going currents (Cl- ion entry through GABA receptors) were recorded. mEPSCs and 
mIPSCs are therefore recorded in the same cells. 
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3.Results 
3.1 Analysis of ?-Pcdh interaction partners 
?-Pcdhs are transmembrane cell adhesion molecules, however, their intracellular 
signaling pathways are not known. It is therefore of key importance to elucidate the 
interaction partners of ?-Pcdhs.  To date only two proteins that interact with the ?-ICD, 
FAK and PYK2, have been identified by yeast two-hybrid screens (Chen et al., 2008).  
The identification of additional proteins would give a broader understanding of ?-Pcdh 
intracellular signaling pathways.  To this end, we decided to identify intracellular ?-Pcdhs 
interaction partners by immunoprecipitation from mouse forebrain lysates, Western blot 
verification of immunoprecipitation efficiency, and subsequent mass-spectrometry 
analysis.  
 
3.1.1 Optimization of Western blot conditions 
Previously in our lab, a polyclonal antiserum was raised against the entire C-terminal, 
constant intracellular domain of ?-Pcdhs.  This antiserum specifically detects full-length 
?-Pcdh in brain lysates (Hambsch et al., 2005). However, a significant level of non-
specific background signals was apparent in Western blot analyses. Since mass 
spectrometry is a highly sensitive method (Hale et al., 2000), a reliable analysis of 
immunoprecipitated binding partners for ?-Pcdhs required substantial reduction of 
background signals.  We therefore used an antibody purification protocol adapted from a 
commercial protocol (SySy, Goetingen, Germany).  Indeed, purification of the antiserum 
greatly reduced non-specific background, as can be seen in Figure 3. The purified 
antibody was deemed sufficiently pure for our purposes.  We continued further with the 
optimization of this antibody for the immunoprecipitation.  
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Figure 3.  ?-Pcdh antibody purification 
Left panel, Western blot probed with unpurified 
?-Pcdh antiserum against HEK 293 cell lysates 
transfected (?-Pcdh A1) or untransfected, and 
against P13 WT and P0 ?-Pcdh KO brain lysates, 
as indicated. Antibody dilution was 1:1000. 
Right panel, similar blot using affinity purified 
antisera. Note, the significant reduction of non-
specific background bands in all 4 lanes. Arrow 
indicates molecular weight of full length ?-Pcdhs. 
15 μg protein lysate was loaded in each lane. 
Molecular weight: kDa. 
 
 
 
 
3.1.2 Optimization of immunoprecipitation conditions 
Antigens may be differentially exposed in immunoprecipitation and Western blotting 
techniques. While Western blotting results in denatured proteins due to detergents and 
reducing chemicals in the loading buffer and gels, immunoprecipitation is performed 
under native conditions, in order to preserve non-covalent protein-protein interactions.  
While we have shown that the denatured epitope is recognized by the antibody, it was 
important to also verify that our purified anti ?-ICD antibody binds to the native protein 
and can be used to immunoprecipitate ?-Pcdhs from mouse brain lysates. In the next step 
we calibrated and optimized immunoprecipitation conditions in order to perform efficient 
and specific co-immunoprecipitation of ?-Pcdhs and their associated protein complexes. 
We started by performing an immunoprecipitation experiment from wild-type (WT) brain 
lysates. Our objective was to obtain as much ?-Pcdh in the eluate fraction as possible.  As 
can be seen in Figure 4, immunoprecipitation was indeed very efficient with our purified 
polyclonal antiserum.  However, using boiling to detach ?-Pcdhs from the antibody-
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beads-complex, we encountered another problem. A large amount of our antibody was 
also released into the eluate fraction, together with the ?-Pcdhs.  An attempt to 
circumvent this problem by a different elution technique, the addition of a large excess of 
purified ?-ICD, was unsuccessful (data not shown). To prevent the release of antibody 
with the antigen, we decided to chemically cross-link with DMP the ?-ICD antibodies to 
the beads. Also, we changed the elution method from boiling to an elution in a low pH 
buffer to disrupt the antibody-antigen interaction. We tested different cross-linking 
protocols by dot-blot analysis (the most efficient of which is described in the Materials 
and Methods section; Figure 4 A). We thus established optimal conditions for the 
immunoprecipitation of the ?-Pcdh from brain lysates, using our polyclonal antibody. 
 
 
Figure 4. Optimization of immunoprecipitation protocol 
A, dot blot analysis for different cross-linking (X-linking) conditions. 5 μg of rabbit antibody were eluted 
in 150 μl of TFA 0.1%, and 5 μl from this (representing ~3%) were blotted onto a PVDF membrane and 
followed up with a secondary antibody and ECL reaction. For better estimation of X-linking efficiency, 
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three more serial dilutions (1:3, 1:9, and 1:27) were performed, and all four conditions were blotted from 
left to right (Shown are two independent experiments in duplicates for each condition). The X-linking 
conditions were: 1, non X-linked; 2, Same X-linked for 30 minutes; 3. X-linked for 30 minutes with double 
amounts of DMP; 4, X-linking for one hour and 5, X-linked with double amounts of DMP for one hour. 
Efficient X-linking is indicated by weaker intensity of dots.. B. Immunoprecipitation (IP) performed under 
X-linking conditions vs. Non X-linking conditions. IP was performed either with the purified ?-Pcdh 
antisrum (left) or with rabbit IgG as control (right).  Western blotting was performed with r ? ?-Pcdh 
antibody. Input, supernatant (Sup), beads and IP fractions are shown. Top band (black arrow, 120 kDa) 
corresponds to ?-Pcdh band. Signal is detected in the input fraction and with higher intensity in the IP 
fraction (left). Right, signal is detected only in the input and sup fractions. Bottom bands show the heavy 
chain of the immunoprecipitating antibody (black arrow, 50 kDa), also detected by the secondary antibody. 
Signal is detected in beads and IP fractions. Under X-linking conditions, signal in the IP fraction is lower 
compared to Non X-linking conditions. Molecular sizes are given in kDa. WB, western blot.  
3.1.3 Mass spectrometry analysis of co-immunoprecipitated proteins 
After having established the optimal conditions for IP, we were ready for the next step in 
our analysis. We pulled down protein complexes from brains of newborn (P0), and adult 
(P42) mice (Figure 5). We chose the two ages with the expectation to find different 
associations of ?-Pcdhs with other proteins during CNS development (P0) and adulthood 
(P42). IPs were performed twice in duplicates for each age. All immunoprecipitated 
fractions were sent for mass-spectrometry analysis to our collaborator (Prof. Guus Smit at 
Vrije Universiteit in Amsterdam).  As a negative control, we performed similar 
experiments with non-specific antibodies (rabbit IgG) and empty beads. 
 
 
 
Figure 5. P0 vs. P42 immunoprecipitation of ?-Pcdhs 
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Top , comparison of IP efficiency from postnatal (P0), and young adult (P42) brains by western blot. Input, 
supernatant (Sup), beads and IP fractions are shown. 10 μl (0.08%) of brain lysate was loaded on a 10% 
protein gel (input and sup. fractions), and 10 μl of the IP fraction (0.8%, equivalent to 100 μl of the input 
fraction).  Strongest signal is detected in the input and IP fractions, and only weak signal in the sup fraction 
in both ages. Bottom, IP with the control, non-specific rabbit IgG antibody. Signal is detected in the input 
and sup, but not in the IP fractions. Western blot was performed with the r ? ?-Pcdh antibody. Molecular 
weight, kDa. WB, western blot. 
   
For the analysis of specific interaction partners we then subtracted the non-specific 
interactors (rabbit IgG; beads alone) from our specific pull-downs (polyclonal anti ?-Pcdh 
antibody).  The specifically interacting proteins from both age-groups are shown in 
Tables 1 and 2. As can be seen in the Tables both age groups yielded similar results. 
Almost all proteins detected in one age group were also detected in the other. This is 
perhaps not entirely unexpected. Mass spectrometry is a highly sensitive method capable 
of picking up minute amounts of protein. A developmental shift in the preference of 
binding partners would not necessarily be detected, as long as ?-Pcdhs are still capable of 
association with both “young” and “mature” proteins. 
 
Table 1 
Proteins identified by IP and MS from P0 mouse brains 
Total # of 
unique 
peptides 
>gi|18087749|ref|NP_291060.1|protocadherin gamma subfamily C, 4 [Mus 
musculus] 
16 
>SART3_MOUSE Squamous cell carcinoma antigen recognized by T-cells 3 - Mus 
musculus (Mouse) 
12 
>gi|148678187|gb|EDL10134.1|mCG133388, isoform CRA_q [Mus musculus] 12 
>gi|148678172|gb|EDL10119.1|mCG133388, isoform CRA_b [Mus musculus] 12 
>gi|18087755|ref|NP_291063.1|protocadherin gamma subfamily A, 2 [Mus 
musculus] 
11 
>KHDR1_MOUSE KH domain-containing, RNA-binding, signal transduction-
associated protein 1 - Mus musculus (Mouse) 
9 
>gi|18087775|ref|NP_291073.1|protocadherin gamma subfamily A, 12 [Mus 
musculus] 
6 
>TM16H_MOUSE Transmembrane protein 16H - Mus musculus (Mouse) 5 
>gi|18087743|ref|NP_291057.1|protocadherin gamma subfamily B, 7 [Mus 
musculus] 
5 
>gi|148678196|gb|EDL10143.1|mCG133388, isoform CRA_z [Mus musculus] 5 
>gi|148678185|gb|EDL10132.1|mCG133388, isoform CRA_o [Mus musculus] 4 
>gi|18087769|ref|NP_291070.1|protocadherin gamma subfamily A, 9 [Mus 
musculus] 
4 
>gi|18087757|ref|NP_291064.1|protocadherin gamma subfamily A, 3 [Mus 
musculus] 
4 
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>ROA1_MOUSE Heterogeneous nuclear ribonucleoprotein A1 - Mus musculus 
(Mouse) 
4 
>gi|18087739|ref|NP_291055.1|protocadherin gamma subfamily B, 5 [Mus 
musculus] 
4 
>ROA2_MOUSE Heterogeneous nuclear ribonucleoproteins A2/B1 - Mus musculus 
(Mouse) 
4 
>FNBP4_MOUSE Formin-binding protein 4 - Mus musculus (Mouse) 4 
>gi|18087753|ref|NP_291062.1|protocadherin gamma subfamily A, 1 [Mus 
musculus] 
3 
>gi|18087741|ref|NP_291056.1|protocadherin gamma subfamily B, 6 [Mus 
musculus] 
3 
>HNRPK_MOUSE Heterogeneous nuclear ribonucleoprotein K - Mus musculus 
(Mouse) 
3 
>gi|32451789|gb|AAH54741.1|Protocadherin gamma subfamily B, 1 [Mus 
musculus] 
3 
>gi|148747499|ref|NP_291065.3|protocadherin gamma subfamily A, 4 [Mus 
musculus] 
3 
>KHDR3_MOUSE KH domain-containing, RNA-binding, signal transduction-
associated protein 3 - Mus musculus (Mouse) 
2 
>TBB4_MOUSE Tubulin beta-4 chain - Mus musculus (Mouse) 2 
>gi|51092283|ref|NP_001003672.1|protocadherin alpha subfamily C, 2 [Mus 
musculus] 
2 
>LSM3_MOUSE U6 snRNA-associated Sm-like protein LSm3 - Mus musculus 
(Mouse) 
2 
>gi|26335715|dbj|BAC31558.1|unnamed protein product [Mus musculus] 2 
>HNRPC_MOUSE Heterogeneous nuclear ribonucleoproteins C1/C2 - Mus 
musculus (Mouse) 
2 
>DPYL1_MOUSE Dihydropyrimidinase-related protein 1 - Mus musculus (Mouse) 2 
>SRBS1_MOUSE Sorbin and SH3 domain-containing protein 1 - Mus musculus 
(Mouse) 
2 
>ADT2_MOUSE ADP/ATP translocase 2 - Mus musculus (Mouse) 2 
>gi|50878294|ref|NP_291068.2|protocadherin gamma subfamily A, 7 [Mus 
musculus] 
2 
>BDH_MOUSE D-beta-hydroxybutyrate dehydrogenase, mitochondrial precursor - 
Mus musculus (Mouse) 
2 
>HNRPG_MOUSE Heterogeneous nuclear ribonucleoprotein G - Mus musculus 
(Mouse) 
2 
>ITAD_MOUSE Integrin alpha-D precursor - Mus musculus (Mouse) 2 
>LSM4_MOUSE U6 snRNA-associated Sm-like protein LSm4 - Mus musculus 
(Mouse) 
1 
>LSM8_MOUSE U6 snRNA-associated Sm-like protein LSm8 - Mus musculus 
(Mouse) 
1 
>LSM2_MOUSE U6 snRNA-associated Sm-like protein LSm2 - Mus musculus 
(Mouse) 
1 
>RUXG_MOUSE Small nuclear ribonucleoprotein G - Mus musculus (Mouse) 1 
>ADT1_MOUSE ADP/ATP translocase 1 - Mus musculus (Mouse) 1 
>TBB2C_MOUSE Tubulin beta-2C chain - Mus musculus (Mouse) 1 
>CALM_MOUSE Calmodulin - Mus musculus (Mouse) 1 
>ATPA_MOUSE ATP synthase subunit alpha, mitochondrial precursor - Mus 
musculus (Mouse) 
1 
>gi|32451623|gb|AAH54555.1|Protocadherin gamma subfamily A, 8 [Mus 
musculus] 
1 
>IRK3_MOUSE G protein-activated inward rectifier potassium channel 1 - Mus 1 
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musculus (Mouse) 
>AT1B1_MOUSE Sodium/potassium-transporting ATPase subunit beta-1 - Mus 
musculus (Mouse) 
1 
>PANK4_MOUSE Pantothenate kinase 4 - Mus musculus (Mouse) 1 
>gi|21426881|ref|NP_619603.1|protocadherin alpha 3 [Mus musculus] 1 
>ELAV4_MOUSE ELAV-like protein 4 - Mus musculus (Mouse) 1 
>NDUA4_MOUSE NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 
4 - Mus musculus (Mouse) 
1 
>SMD1_MOUSE Small nuclear ribonucleoprotein Sm D1 - Mus musculus (Mouse) 1 
>HNRPD_MOUSE Heterogeneous nuclear ribonucleoprotein D0 - Mus musculus 
(Mouse) 
1 
>CHKA_MOUSE Choline kinase alpha - Mus musculus (Mouse) 1 
>DGKB_MOUSE Diacylglycerol kinase beta - Mus musculus (Mouse) 1 
>K1967_MOUSE Protein KIAA1967 homolog - Mus musculus (Mouse) 1 
>AP2A2_MOUSE AP-2 complex subunit alpha-2 - Mus musculus (Mouse) 1 
>KIF27_MOUSE Kinesin-like protein KIF27 - Mus musculus (Mouse) 1 
>LRC50_MOUSE Leucine-rich repeat-containing protein 50 - Mus musculus 
(Mouse) 
1 
>ELAV3_MOUSE ELAV-like protein 3 - Mus musculus (Mouse) 1 
>gi|149262345|ref|XP_001478262.1|PREDICTED: hypothetical protein [Mus 
musculus] 
1 
 
Table 1 
Mass spectrometry (MS) results for immunoprecipitated ?-Pcdhs binding proteins performed in P0 mice. 
Left column indicates the full ID of the proteins detected by MS, Right column indicates the total number 
of unique peptides detected for each protein, which is a measure of the level of confidence.  
 
 
Table 2 
Proteins identified by IP and MS from P42 mouse brains 
Total # of 
unique 
peptides 
>SART3_MOUSE Squamous cell carcinoma antigen recognized by T-cells 3 - Mus 
musculus (Mouse) 
16 
>gi|18087751|ref|NP_291061.1|protocadherin gamma subfamily C, 5 [Mus 
musculus] 
11 
>KHDR1_MOUSE KH domain-containing, RNA-binding, signal transduction-
associated protein 1 - Mus musculus (Mouse) 
10 
>gi|148678187|gb|EDL10134.1|mCG133388, isoform CRA_q [Mus musculus] 8 
>gi|18087775|ref|NP_291073.1|protocadherin gamma subfamily A, 12 [Mus 
musculus] 
6 
>STUB1_MOUSE STIP1 homology and U box-containing protein 1 - Mus musculus 
(Mouse) 
6 
>gi|148678196|gb|EDL10143.1|mCG133388, isoform CRA_z [Mus musculus] 5 
>gi|18087755|ref|NP_291063.1|protocadherin gamma subfamily A, 2 [Mus 
musculus] 
5 
>gi|148678177|gb|EDL10124.1|mCG133388, isoform CRA_g [Mus musculus] 4 
>IRK3_MOUSE G protein-activated inward rectifier potassium channel 1 - Mus 
musculus (Mouse) 
4 
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>IRK9_MOUSE G protein-activated inward rectifier potassium channel 3 - Mus 
musculus (Mouse) 
4 
>BDH_MOUSE D-beta-hydroxybutyrate dehydrogenase, mitochondrial precursor - 
Mus musculus (Mouse) 
4 
>E41L3_MOUSE Band 4.1-like protein 3 - Mus musculus (Mouse) 3 
>TBB5_MOUSE Tubulin beta-5 chain - Mus musculus (Mouse) 3 
>gi|148678172|gb|EDL10119.1|mCG133388, isoform CRA_b [Mus musculus] 3 
>gi|18087757|ref|NP_291064.1|protocadherin gamma subfamily A, 3 [Mus 
musculus] 
3 
>GHC1_MOUSE Mitochondrial glutamate carrier 1 - Mus musculus (Mouse) 2 
>IRK6_MOUSE G protein-activated inward rectifier potassium channel 2 - Mus 
musculus (Mouse) 
2 
>TBB2B_MOUSE Tubulin beta-2B chain - Mus musculus (Mouse) 2 
>gi|18700024|ref|NP_570954.1|isocitrate dehydrogenase 3, beta subunit [Mus 
musculus] 
2 
>TM16H_MOUSE Transmembrane protein 16H - Mus musculus (Mouse) 2 
>gi|18087753|ref|NP_291062.1|protocadherin gamma subfamily A, 1 [Mus 
musculus] 
2 
>EAA2_MOUSE Excitatory amino acid transporter 2 - Mus musculus (Mouse) 2 
>gi|50878294|ref|NP_291068.2|protocadherin gamma subfamily A, 7 [Mus 
musculus] 
2 
>GNAO1_MOUSE Guanine nucleotide-binding protein G(o) subunit alpha 1 - Mus 
musculus (Mouse) 
2 
>BANP_MOUSE Protein BANP - Mus musculus (Mouse) 2 
>gi|44890274|gb|AAH66823.1|Pcdhgb7 protein [Mus musculus] 2 
>AT1A3_MOUSE Sodium/potassium-transporting ATPase subunit alpha-3 - Mus 
musculus (Mouse) 
2 
>RSMN_MOUSE Small nuclear ribonucleoprotein-associated protein N - Mus 
musculus (Mouse) 
2 
>gi|86476054|ref|NP_001034474.1|VGF nerve growth factor inducible [Mus 
musculus] 
1 
>LYSCP_MOUSE Lysozyme C type P precursor - Mus musculus (Mouse) 1 
>ROA3_MOUSE Heterogeneous nuclear ribonucleoprotein A3 - Mus musculus 
(Mouse) 
1 
>TBB2C_MOUSE Tubulin beta-2C chain - Mus musculus (Mouse) 1 
>1433Z_MOUSE 14-3-3 protein zeta/delta - Mus musculus (Mouse) 1 
>gi|3253071|dbj|BAA29046.1|CNR2 [Mus musculus] 1 
>68MP_MOUSE 6.8 kDa mitochondrial proteolipid - Mus musculus (Mouse) 1 
>gi|18087735|ref|NP_291053.1|protocadherin gamma subfamily B, 2 [Mus 
musculus] 
1 
>LSM8_MOUSE U6 snRNA-associated Sm-like protein LSm8 - Mus musculus 
(Mouse) 
1 
>RUXE_MOUSE Small nuclear ribonucleoprotein E - Mus musculus (Mouse) 1 
>EAA1_MOUSE Excitatory amino acid transporter 1 - Mus musculus (Mouse) 1 
>DNM1L_MOUSE Dynamin-1-like protein - Mus musculus (Mouse) 1 
>NPTN_MOUSE Neuroplastin precursor - Mus musculus (Mouse) 1 
>LSM3_MOUSE U6 snRNA-associated Sm-like protein LSm3 - Mus musculus 
(Mouse) 
1 
>MPCP_MOUSE Phosphate carrier protein, mitochondrial precursor - Mus musculus 
(Mouse) 
1 
>gi|18087769|ref|NP_291070.1|protocadherin gamma subfamily A, 9 [Mus 
musculus] 
1 
Results 
29 
>gi|51092283|ref|NP_001003672.1|protocadherin alpha subfamily C, 2 [Mus 
musculus] 
1 
>CSR2B_MOUSE Cysteine-rich protein 2-binding protein - Mus musculus (Mouse) 1 
 
Table 2 
Mass spectrometry (MS) results for immunoprecipitated ?-Pcdhs binding proteins performed in P42 mice. 
Left column indicates the full ID of the proteins detected by MS, Right column indicates the total number 
of unique peptides detected for each protein, which is a measure of the level of confidence.  
 
In order to assign the wide spectrum of proteins detected in our analyses to specific 
signaling pathways, the data need to be sorted within a logical framework.  Thus, we 
divided ?-Pcdh interacting proteins of both age groups, into known signaling networks, 
and constructed a plausible interaction diagram (NCBI protein database, GeneCards 
database http://www.genecards.org/, and references therein for each protein) (Figure 6).  
Proteins of unknown biological function (e.g. TM16H) and proteins which could not be 
integrated into known signaling networks (e.g. ELAV), as well as some proteins with 
redundant functions (e.g. different GIRK proteins), are omitted from analysis for clarity.  
We also omitted proteins with ubiquitous functions such as Tubulin or Calmodulin.  Our 
final interaction diagram represents, therefore, what we consider to be the most 
“physiologically sound” core interaction data. We were thus left with a workable number 
of proteins, which we next proceeded to test further for interaction with ?-Pcdhs. 
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Figure 6. ?-Pcdh interacting proteins: functional grouping and known interactions 
Diagram of ?-Pcdh interacting proteins sorted into functional groups according to their known biological 
function. Main groups shown contain the KH domain containing RNA binding proteins (Sam68 and SLM-
2, and other associated proteins, light green rectangles), the G-protein coupled receptor channel Kir3.1 and 
G(o)-proteins (purple rectangles), and the splicing associated proteins such as SART3 (light blue 
rectangles). Elipses indicate major components of the cell (RNA and Cellular junctions) with which the 
different protein groups show an association (hatched lines between proteins known to associate with these 
functions and the function itself).  Solid lines indicate a known direct protein-protein interaction. Dotted 
lines indicate an indirect protein-protein interactions. 
 
3.1.4 Verification of  mass spectrometry results using co-immunoprecipitation 
The verification of any protein-protein interaction was essential for us to seriously 
consider a possible role for the binding proteins downstream to ?-Pcdhs. This is 
especially true for mass-spectrometry, as it is an extremely sensitive method leading to a 
high number of false-positive interactions. We therefore decided to corroborate mass-
spectrometry data by use of biochemical tools. We first screened the publically available 
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antibody databases for commercial antibodies that can be used for co-
immunoprecipitation. We chose antibodies for at least one protein in each of the 3 main 
interaction groups (Figure 6), which were: goat ? SART3, goat ? SORBS1, mouse and 
rabbit ? Sam68, goat and rabbit ? SLM-2, and rabbit ? GIRK1/Kir3.1. 
We first wanted to test whether we can efficiently use these antibodies to 
immunoprecipitate their respective antigens. We immunoprecipitated from mouse brain 
lysates as described before, and then performed Western blot analysis for the proteins. 
The manufacturer’s instructions specified that the antibodies against SART3, SRBS1 and 
GIRK1/Kir3.1 do not work for immunoprecipitation, We could therefore only initially 
test immunoprecipitation for Sam68 and SLM-2. This was successful in both cases as 
shown, on the Western blot in Figure 7, albeit at a lower efficiency compared with 
immunoprecipitation preformed with the rabbit anti-?-Pcdh antibody (as judged by a 
relatively large amount of non-immunoprecipitated protein in the Sup. fraction, and a 
weaker relative intensity of the IP band; Figure 7). 
 
Figure 7. Immunoprecipitation of Sam68 
and SLM-2 
Western blot after IP from mouse brain lysates 
performed with m ? Sam68 (left), and g ? 
SLM-2 (right) antibodies. Immunoreactive 
bands were detected with r ? Sam68 and r ? 
SLM-2 antibodies, respectively.  Input, 
supernatant (Sup), beads and IP fractions are 
shown. Left panel, signal is detected in all 
fraction, with highest intensity in the IP 
fraction. Right panel, signal is detected in the 
input, sup and IP fractions. Antibody specific 
bands are marked with an arrow. Molecular 
weight: kDa. WB: Western Blot. IP: 
Immunoprecipitation. 
 
The critical question was whether we could co-immunoprecipitate the ?-Pcdhs together 
with the detected interaction partners. In the next step, we performed 
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immunoprecipitations with antibodies against Sam68 and SLM-2 and detected with the ?-
Pcdh antibody, or vice-versa. For verifying the interaction of ?-Pcdh with the 
GIRK/Kir3.1 protein, we used the polyclonal anti ?-Pcdh antibody for 
immunoprecipitation, and the anti GIRK/Kir3.1 antibody for Western blotting detection. 
These experiments confirmed an interaction of ?-Pcdhs with Sam68, SLM-2, and 
GIRK/Kir3.1, as shown in Figure 8. We had also tried to immunoprecipitate using the 
anti ?-Pcdh antibody, and detect the SART3 and SRBS1 with specific antibodies, but 
Western blotting with these antibodies did not yield specific bands from mouse brain 
lysates (not shown). 
 
Figure 8. Co-immunoprecipitation of ?-Pcdh 
interacting proteins 
Western blot analysis with one antibody following 
immunoprecipitation with other antibodies (Co-IP). 
A. Co-IP experiments for ?-Pcdhs with SLM-2 
(top), Sam68 (middle), and Kir3.1 (bottom). Top 
panel, IP was preformed with the g ? SLM-2 
antibody and Western blot with the r ? ?-Pcdh 
antibody. Middle panel, IP was preformed with the r 
? ?-Pcdh antibody and Western blot with the m 
? Sam68 antibody. Bottom panel, IP was preformed 
with the r ? ?-Pcdh antibody and Western blot with 
the r ? Kir3.1 antibody. Input, supernatant (Sup), 
beads and IP fractions are shown; immunoreactive bands can be detected in all fractions. B. Western 
blotting with the r ? Kir3.1 antibody shows two bands (left, lane loaded with 20 μg lysate). Pre-incubation 
of the r ? Kir3.1 antibody with the target (a Kir3.1-GST-fusion protein) eliminates the specific (lower) 
band (marked with an arrow). Molecular weight: kDa. WB: Western Blot. IP: Immunoprecipitation. 
 
Taken together, our data verify the interaction of ?-Pcdhs with at least two functional 
protein groups, the KH domain containing, RNA binding proteins (Sam68 and SLM-2), 
and the G-protein coupled, inward rectifying potassium channels (GIRK/Kir3.1). At this 
point, we decided to attempt and ascertain the role of these protein interactions in vivo. 
To this end we needed to establish a way to deliver functional and putative binding 
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mutants of these proteins into the developing mouse brain, in order to establish the effect 
of these specific proteins and their interaction with ?-Pcdh on the development of brain 
circuitry and synaptogenesis. 
 
3.2  Establishment of a method for transduction of neurons by targeted recombinant 
virus injections into neonatal mouse brains 
As our main goal in this work was to study the intracellular signaling pathways of ?-
Pcdhs in vivo, we required a highly reproducible, high throughput method to overexpress 
?-Pcdhs and their interaction partners. To this end we have developed a rAAV based 
injection method, which allows us to transduce different regions in the brains of neonates 
(P0). This is especially important since ?-Pcdh knock-out mice die shortly after birth, 
precluding the analysis of signaling pathways in the postnatal brain.  Viral induction in 
the neonate brain could be used to create a “viral” conditional knock-out of ?-Pcdhs, by 
injection of Cre recombinase expressing rAAV into the brains of a ?-Pcdh 2-lox line (?-
Pcdh
2lox). By applying this method we demonstrated that we could overexpress the full-
length ?-Pcdh A1 protein, however more efficiently the constant intracellular domain of 
?-Pcdh (?-ICD) in vivo in the brain. 
 
3.2.1 Establishment of targeted, reproducible injections into the neonatal mouse 
brain  
The establishment of any reproducible system requires that one can compare different 
experiments. In order to standardize virus injections into the P0 mouse brain we first 
generated a neonatal brain atlas (for C57/Bl6) to establish coordinates for exact targeting 
of the injection needle into different brain regions (Figure 9). Such a brain atlas already 
exists for adult mice (Paxinos et al., 1980), but not yet for neonates.  
We fixed whole heads from newborn mice in 4% PFA, stained coronal and saggital 
sections (200μm) with Nissl dye (see Materials and Methods) and serially arranged them 
on microscope slides (Figure 9 A). These sections constitute a miniature brain atlas that 
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can be used for injection into neonatal mice. Most major structures are visible from the 
Nissl staining (e.g. hippocampus, ventricles, olfactory bulb). 
In order to determine the coordinates for needle insertion into the different brain regions 
we utilized the well defined Lambda demarcation, clearly visible on top of a neonatal 
mouse, as morphological landmark (Figure 9) and calculated the anterior/posterior (A/P), 
medial/lateral (M/L) and dorsal/ventral (D/V) distances to target different brain structures 
(Figure 9).  
 
Figure 9. Mouse P0 brain atlas 
A. Nissl stained, 200μm thick, serially 
arranged coronal sections of a P0 mouse head 
are arranged in a circle. Schematic diagram in 
the center of the circle illustrates the lambda 
demarcation (?) and the coordinates for 
targeted frontal cortex (FC), ventricular 
(Ven), hippocampal (HPc) and cerebellar 
(CB) injections, marked with asterisks. 
Distances and scale bar are given in mm; 
HPc, hippocampus; Ven, ventricle; FC, 
frontal cortex; CB, cerebellum; OB, olfactory 
bulb; ?, lambda. 
B. Top panels, dorsal view of a P0 mouse 
head and brain with the main brain sutures 
drawn to scale on top. Asterisks indicate the 
rostro-caudal points of needle insertion. Right 
side, shows the actual proportions of a 33 
gauge bevelled needle used for targeted virus 
injections. Bottom panels illustrate the 
respective coronal brain sections for 
hippocampal and ventricular injection, with 
the needle superimposed in the precise 
injection location drawn to scale for 
visualization. P0, postnatal day zero; CB, 
cerebellum; CTX, cortex; OB, olfactory bulb.   
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As the volume of virus-containing solution and the speed of injection are critical 
parameters for efficient infection, we constructed an injection setup by utilizing a 
standard WPI infusion-pump, controlling a 50 μl syringe connected with plastic tubing to 
a “needle holder” equipped with a 34 gauge beveled needle (Figure 10). The injection 
speed was controlled by a standard WPI controller operated with a foot switch. To 
determine the correct D/V position (depth) of the needle-tip, we marked the endpoint on 
the needle with a water-resistant pen. We have thus obtained the necessary equipment, 
coordinates, and demarcations, to drive viruses into specific regions of the neonatal 
mouse brain. 
Figure 10. Injection setup 
Picture of the P0 virus injection 
setup. Left side, microinjection 
pump holding a 50 ml  syringe, and 
digital control panel from WPI. 
Right side, heat plate used for 
restoring body temperature and 
normal circulation to the pups.  
Styrofoam pup holder used to 
immobilize anesthetized pups during 
injection, and injection needle 
connected by thin tubing to the 
pump are shown right to digital 
control panel.  Also shown is a felt-tip pen used for marking the injection site on the head surface.  Foot 
pedal is not shown. 
3.2.2 Characterization of virus-infected brain regions  
When using viruses to deliver transgenes into the brain, the question arises is as to how 
well different regions can be targeted. In order to test the targeting specificity and virus 
diffusion upon ventricular, hippocampal, olfactory bulb and cerebellar injections, we used 
heterozygous Rosa26+/- neonates injected with rAAV8 pseudotyped virus expressing Cre-
recombinase under the control of a human synapsin core promoter/enhancer element. 
Cells carrying the ‘stop-floxed’ Rosa26 reporter allele turn dark blue after Cre-mediated 
recombination and subsequent X-gal staining (Soriano, 1999). Before injections, newborn 
heterozygous Rosa26+/- pups (2-5 hours after delivery) were separated from the mother 
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and wrapped for 3-5 minutes in a paper towel covered with wet-ice to anesthetize and 
immobilize them. Immediately thereafter, pups were placed onto a custom made 
‘styropore mold’ to fix them into an appropriate position for subsequent virus injections. 
1 or 2 μl of purified rAAV8 (1011 genomes/ml) containing solution were infused into the 
lateral ventricles (from Lambda:1 mm rostral, 1 mm lateral, 1.5 mm ventral; n=10), 0.5 μl  
of rAAV8 into the hippocampus (from Lambda: 2 mm rostral, 0.7 mm lateral, 1.8 mm 
ventral; n=8) or 1 μl of rAAV8 into the cerebellum (from Lambda: 1 mm caudal, 2 mm 
ventral; n=6) of neonates at a speed of 125 nl/sec, through a 34 gauge beveled needle. 
After injections, the needle was kept in place for additional ~3 seconds to avoid backflow 
of virus containing solution. The speed of the injection and the width of the needle were 
both important, as faster injection speed and/or thicker needles resulted in significant 
backflow of virus-solution through the injection channel, immediately after removal of 
the needle. Following injection, the pups were placed on a 37°C warming plate for 
recovery. After all newborns were fully motile, they were returned to their mother as a 
group. In most cases the mother accepted the injected pups and fostered them. Injection 
of a typical litter (6-10 pups) took about 15-20 minutes. Three weeks after injection, mice 
were genotyped and Rosa26+/- mice were used to determine infection and targeting 
efficiency after vibratome sectioning and subsequent X-gal staining.  
Figure 11 shows X-gal staining in Rosa26 pups on brain sections (100 μm) after targeted 
virus delivery into different brain regions.  Ventricular injection with a high-titer virus 
resulted in efficient infection of the entire dorsal forebrain, hippocampus, and some cells 
in the olfactory bulb (Figure 11 A). Additionally, we tested different virus titers, which 
enabled us to control the density of infection (Figure 11 B,C).  Our results show that 
targeted injection can be used to achieve efficient infection of selected brain regions such 
as hippocampus (Figure 11 D), olfactory bulb (Figure 11 F), and cerebellum, yet the latter 
was not efficiently transduced upon ventricular injections (Figure 11 G). 
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Figure 11. Efficient infection of 
selected brain areas 
A. X-gal stained (blue) parasaggital 
section of a heterozygous Rosa26+/- 
mouse brain after ventricular P0 
rAAV8.Syn.Cre (2μl, 1x108 
particles/μl) injection. Robust 
staining can be detected in all dorsal 
forebrain structures and the mitral 
cell layer of the olfactory bulb. B. 
Coronal section (-2mm from 
bregma) showing robustly infected 
cortex and dorsal hippocampus after 
ventricular injection at P0 with 2μl 
(1x108 particles/μl) and in C sparse 
infection of a corresponding region 
infected with 2μl (1x107 
particles/μl) of rAAV8.Syn.Cre. D. 
Staining of a coronal brain section 
after targeting the dorsal 
hippocampus at P0. E. High 
magnification image of a heavily 
infected cortical region shown in B 
demonstrating the maximum density 
of infection. F. Staining of a saggital 
section through the mitral cell layer 
of the olfactory bulb at high 
magnification. G. Staining of a 
saggital section through the 
cerebellum demonstrating the 
selective transduction of Purkinje cells after cerebellar targeting at P0. In all cases mice were sacrificed 
21 days after virus delivery.  
 
In summary, we were now able to inject either specific brain regions, or the entire 
neocortex. This affords us a powerful tool for specific and global “viral transgenics”.  
Results 
38 
3.2.3 Onset and duration of fluorescent protein expression  
As our interests lie in the function of ?-Pcdhs in the developing mouse brain, we had to 
determine how early expression from the viral constructs can be detected. To determine 
the exact onset and duration of protein expression after rAAV8 mediated gene transfer 
into P0 mouse brains, we injected virus expressing a Venus fluorescent reporter protein 
driven by the human synapsin core promoter/enhancer element into the lateral ventricles 
as described above. Brains from injected mice were removed and PFA-fixed, 24, 48 
hours, seven days, and 4 months after virus injection (Figure 12). Coronal sections were 
stained with a polyclonal antibody against GFP to increase detection sensitivity for 
subsequent analysis under a fluorescent microscope. Fluorescent cortical neurons could 
be readily detected as early as 24 hours after virus delivery, though fluorescence intensity 
and numbers of infected cells increased with time (Figure 12). A related issue that we 
considered had to do with the fact that rAAV remains in an episomal state, and does not 
integrate into the host genome, raising the question whether virus DNA will remain stable 
in neurons after a long time period.  To answer this question, we monitored fluorescent 
protein expression during puberty and adulthood. Figure 12 E illustrates robust long-
lasting expression of the Venus reporter protein up to 4 months after injection. No 
obvious loss of Venus fluorescence was detected in the cortex when compared with 
comparable cortical regions stained at earlier time points. These experiments demonstrate 
fast, efficient and long-lasting expression of a fluorescent reporter-protein after rAAV8 
mediated transduction of neonatal mouse brain neurons. The very early onset of 
expression allows us to use this system to study the developmental aspects linked with ?-
Pcdhs. 
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Figure 12. Timecourse of viral 
expression 
A. Coronal brain section of P0 
mouse at the approximate focus of 
injection. Overlayed window 
illustrates the general region from 
which the following images were 
taken. B. Anti-GFP stained coronal 
section of the dorsal cortex 24 hours 
after ventricular rAAV8.Syn.EGFP 
delivery at P0 showing the first 
appearance of fluorescently labeled 
neuronal cell bodies mainly in upper 
cortical layers. C. Same after 36 hrs. 
D. The intensity of fluorescence as 
well as the number of labeled 
neurons in the cortex increase with 
time, reaching a maximum of 
infection at ~P7. Note that at P7 
fluorescently labeled neurons and 
their neurites are clearly visible also 
in deep cortical layers. E. Robust 
fluorescent labeling is still  present 
4 months after virus  delivery. Scale 
bar is 100μm.  
 
3.2.4 Virus distribution after parenchymal injection into the neonatal brain 
Our data on proteins interacting with ?-Pcdhs were obtained using immunoprecipitation 
from WT mice. This requires a relatively large and homogenous region of expression in 
the brain. To this end, we needed to determine the volume of the tissue that could be 
dissected and analyzed after efficient viral transduction. To investigate virus diffusion 
around the injection site into the parenchyma of the frontal cortex (from Lambda: 3.5 mm 
anterior, 0.5 mm lateral, 0.7 mm ventral; n=5) we bilaterally delivered 1 μl rAAV8 (1011 
genomes/ml), expressing the fluorescent Venus reporter protein with an injection rate of 
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80 nl/sec. Forty two days later, 100 μm thick coronal sections were analyzed for Venus 
expression. Figure 13 A shows the distribution and density of Venus expressing neurons 
~2 mm from injection site along the A/P axis of the brain. Note that no fluorescent 
neurons could be detected in the hippocampus, thus excluding possible miss-targeting of 
virus into the lateral ventricles. The density graph depicted in Figure 13 G shows the 
infection density as a function of the distance from the injection point. These data 
demonstrate that a region of 1mm around the injection site can be efficiently transduced 
upon parenchymal injections. Most notably, the number and position of infected neurons 
are highly reproducible (n=5); differences in virus spread and infection efficacy between 
different mice injected into similar coordinates were not significant. In summary, focal, 
targeted expression can be achieved upon injection of rAAV8 into the brain parenchyma. 
The areas transduced span a significant portion of the mouse forebrain and should contain 
enough exogenous protein for biochemical analyses. 
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Figure 13. Virus distribution after forebrain injection 
A-F. Anti GFP stained coronal sections of the frontal cortex 42 days after ventricular rAAV8.Syn.EGFP 
delivery at P0. Fluorescently labeled neurons can be detected 2.2mm from the injection spot (inset shows 
an overview of the area; A), with increasing density of fluorescent neurons at 1.5- (B, inset) and 0.6mm (C, 
inset). Highest viral transduction can be seen at the point of virus delivery (D, inset). The number of 
infected neurons decreases again linearly with -1.3- (E, inset) and -2.1mm (F, inset) distance from injection 
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spot. Inset in panel F shows that the dorsal hippocampus (stained against NeuN in red) was not infected by 
the virus. Scale bar is 500μm. G. Quantification of infection efficacy as a function of the distance from the 
injection point. At 0 mm (injection point) ~60% of all neurons express EGFP (number of virally 
transducted green fluorescent neurons divided by the total number of neurons identified by NeuN staining). 
The number of virally infected neurons decreases linearly on both sides with increasing distance from the 
point of injection.  
 
3.2.5 Expression of full-length ?-Pcdh in the neonatal mouse brain 
The viral delivery system described above enabled us to overexpress proteins in the 
neonatal mouse brain. In our immunoprecipitation experiments, we used a polyclonal 
antibody directed against the ?-ICD. This has the drawback that the binding of the 
antibody to the ?-Pcdhs might mask some of the intracellular interactions we were 
searching for. Alternatively, excess antibody may compete with the endogenous binding 
proteins for the binding sites on the surface of the ?-ICD. We therefore attempted to 
overexpress ?-Pcdh A1 in a tagged version and immunoprecipitate it with a specific 
antibody directed against the tag. A triple-Flag tag was fused to the C-terminus of ?-Pcdh 
A1 (?-Pcdh A1-3X Flag). We used the rAAV-based bidirectional tetracycline regulated 
expression system described in Zhu et al. (2007). Using this approach, we wanted to 
replace the endogenous ?-Pcdh with the exogenous tagged version, by injecting the virus 
into the ?-Pcdh 2-lox mouse line in combination with a Cre recombinase expressing 
rAAV. The original bidirectional vector encodes a Venus fluorescent protein and the Cre 
recombinase, bidirectionally controlled by a tetracycline-transactivated minimal promoter 
(Figure 14 A1). Expression of both proteins is initiated by co-injection of an activator 
virus that expresses the tetracycline dependent transactivator (tTA) under the control of a 
neuron specific promoter (Zhu et al., 2007). We first replaced Venus with ?-Pcdh-A1-3X 
Flag, in order to create the replacement vector encoding both the tagged exogenous ?-
Pcdh, and Cre recombinase (Figure 14 A2). However, no Flag tag signal could be 
detected after this construct had been injected into neonatal mouse brains, although Cre 
recombinase was (not shown). A possibility which we considered was that the 
bidirectional promoter displays a preference of expression to one side, thus favoring the 
expression of one cassette. To test this hypothesis, we also cloned the ?-Pcdh-A1-3X Flag 
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instead of the Cre recombinase (Figure 14 A3). In this construct we obtained Venus 
fluorescence but no Flag signal was detected here either. We attribute this to the 
relatively large size of ?-Pcdh-A1 (112kDa), which may bias relative expression levels 
using this system. 
 
 
Figure 14. Vectors used for virus mediated expression of ?-Pcdh A1  
A. Original plasmid from Zhu et al. (2007) (1). The bidirectional minimal promoter drives expression of the 
Venus fluorescent protein and Cre recombinase in opposite directions. (2) Venus cassette replaced by ?-
Pcdh A1-3x Flag or (3) Cre recombinase cassette replaced by ?-Pcdh A1-3x Flag. B. Unidirectional vector 
from Kugler et al. (2003) ?-Pcdh A1-3X Flag expressed under the control of the human synapsin promoter. 
AmpR, Ampicillin resistance cassette. Molecular sizes in bp. 
 
As an alternative approach, we utilized a unidirectional vector and cloned the sequence 
for ?-Pcdh-A1-3X Flag downstream of the human synapsin promoter. The synapsin 
promoter that we used was shown to drive expression specifically in principal neurons 
using the rAAV gene delivery system (Kugler et al. (2003), Figure 14 B). As this vector 
does not contain a fluorescent marker, we injected rAAV8.Syn.?-Pcdh-3X Flag together 
with a rAAV8 expressing the red fluorescent Tomato reporter protein under the same 
promoter. We succeeded to detect ?-Pcdh-A1-3xFlag using a specific antibody directed 
against the triple Flag tag (monoclonal anti-Flag antibody). Furthermore, the fluorescent 
Tomato signal and Flag immunostaining overlapped completely, demonstrating efficient 
expression of two proteins in the same neurons, which may also be used to co-express 
Cre (Figure 15 A-C).  
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In order to establish an endogenous ?-Pcdh replacement system, we had to verify that we 
obtain enough exogenous protein, and are able to immunoprecipitate it from injected 
brain lysates. We injected brains with the virus encoding the tagged ?-Pcdh A1, and 
attempted to immunoprecipitate it with the commercial Flag antibody. As can be seen in 
Figure 15 D (lower panel), we managed to efficiently immunoprecipitate ?-Pcdh-A1-3X 
Flag. However, the amount of tagged immunoprecipitated ?-Pcdh-A1-3X Flag was very 
small, compared to endogenous ?-Pcdh (Figure 15 D; compare intensity of Input fraction 
in the left upper panel and the IP fraction). In summary our data indicate that low 
molecular weight proteins are much more efficiently expressed using this method. We 
therefore tried to use it for expressing the putative signaling domain of the ?-Pcdhs, the ?-
ICD. We first used local injection and immunostaining for the ?-ICD in order to visualize 
overexpression in vivo. To this end, we also decided to raise specific monoclonal 
antibodies as our polyclonal antibody is not suitable for these purposes. 
 
Figure 15. Targeted 
expression of ?-Pcdh A1-
3X Flag in cortex by 
neonatal injection 
A-C. Fluorescent Images of 
coronal sections from mice 
after injection with ?-Pcdh 
A1-3X-Flag and ‘Tomato’ 
expressing viruses. Red 
channel shows Tomato 
expression (A). Green 
channel shows 
immunostaining of ?-Pcdh 
A1-3X Flag tag (B). Co-
localization (yellow) can be 
seen in the overlay of both channels (C). Scale bar is 100 μm. D. Western blot following 
imunnoprecipitation from mouse brain lysates three weeks after neonatal virus injection, compared to non 
injected control, using the monoclonal anti-Flag antibody; input, supernatant (Sup), beads and IP fractions 
are shown. Top panel: Western blotting using r ? ?-Pcdh; endogenous levels of ?-Pcdhs are unchanged by 
viral expression of ?-Pcdh A1, as can be seen by comparing the input fractions between injected and control 
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mouse brain lysates. IP fraction from injected mouse using the monoclonal anti-Flag antibody shows a 
weak band. No signal is detected in the IP fraction of the control mouse. Bottom panel: Western blot with 
the monoclonal anti-Flag antibody shows signal in all fractions of the injected mouse. IP fraction shows 
highest signal intensity indicating efficient pull down. No signal is detected in fractions from the control 
mouse. WB: Western Blot. IP: Immunoprecipitation. 
 
3.2.6 ?-ICD injection and staining in brain using specific monoclonal antibodies 
Overexpression of the ?-ICD differs conceptually from replacement of the full-length 
protein. A high level of overexpression is required to yield a dominant phenotype. Our 
polyclonal antibody cannot be used for immunostaining (not shown). We therefore raised 
monoclonal antibodies targeted against the ?-ICD together with Synaptic Systems (SySy, 
Goettingen, Germany). Next, we injected a virus encoding the ?-ICD (rAAV8.Syn.c-
Myc-?-ICD.IRES.Venus) into WT mice in order to overexpress the protein. For seeing 
whether we could detect endogenous levels of ?-Pcdh, we used a virus encoding Cre 
(rAAV8.Syn.Cre.IRES.Venus) and injected that into ?-Pcdh2lox mice in order to reduce 
endogenous ?-Pcdhs to a minimum. As a control, WT mice were also injected with the 
Cre encoding virus. Both viruses also encode a Venus marker. Brains were sliced and 
stained in parallel with the different monoclonal anti ?-ICD antibodies (12 clones). One 
of these clones (no. 317) showed positive results in immunostainings of brain sections 
(Figure 16). Using this antibody we could detect overexpressed ?-ICD, but not 
endogenous levels of ?-Pcdh (no difference was seen between WT and ?-Pcdh2lox injected 
mice). Based on our results we suspect that the antibody may not be sensitive enough to 
detect endogenous protein over the background. Alternatively, endogenous levels of the 
?-Pcdhs may be very low. ?-ICD was, however, very efficiently overexpressed. 
For immunoprecipitation of the ?-ICD it would be preferable to have a monoclonal 
antibody, as the chances that it would mask putative interaction zones is lower than a 
polyclonal antibody, since it only has a single recognition epitope. In addition, the use of 
different antibodies for the immunoprecipitation and subsequent Western blotting 
prevents the unwanted detection of non-specific heavy chains of the immunoprecipitating 
antibody. We therefore also tried to immunoprecipitate ?-Pcdhs from WT brain lysate 
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using the monoclonal ?-Pcdh antibody. Figure 16 D shows that we achieved efficient 
immunoprecipitation.  
 
Figure 16. Immunostaining and 
immunoprecipitation using 
monoclonal anti ?-Pcdh antibodies 
A-C. Coronal sections of the Dentate 
Gyrus (DG) showing an overlay 
fluorescent image of Venus (green) 
and immunostaining signal with 
monoclonal antibody (clone number 
317) raised against the ?-ICD (red). 
A. Coronal section of the DG from a 
?-Pcdh2lox mouse injected with a 
virus expressing the ?-ICD shows 
intense co-labeling (yellow) in 
neurons. B. WT mouse injected with 
a virus encoding the Cre 
recombinase was used as a control to visualize endogenous ?-Pcdh imunostaining levels. Immunostaining 
signal is very weak (red). C. Deletion of endogenous ?-Pcdhs by injection of a Cre recombinase expressing 
virus into ?-Pcdh2lox neonate. Immunostaining intensity is not visually distinguishable from WT control 
slices (B). D. Western blotting following immunoprecipitation using monoclonal anti ?-Pcdh antibody from 
WT brain lysate; input, supernatant (Sup), beads and IP fractions are shown.  Top panel, IP with the m ? ?-
Pcdh antibody. Signal is detected in all fractions, IP fraction shows highest intensity. Bottom panel, IP with 
the control antibody (non-specific rabbit IgG). Immunoreactive signal is detected for the input and sup 
fractions only. Western blotting was preformed with the r ? ?-Pcdh antibody. WB: Western blot, IP: 
Immunoprecipitation. 
 
In conclusion, the production of monoclonal antibodies has afforded us a tool for 
improving immunoprecipitation of ?-Pcdhs and immunodetection of virally 
overexpressed ?-ICD in brain slices. 
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3.2.7 Successful overexpression of the C-terminal domain ?-Pcdh in P0 mice 
Our expression data show that we can express large proteins such as the full-length ?-
Pcdh, but only at a low level. In light of this, we decided to overexpress only the small 
putative signaling domain of the ?-Pcdhs, the ?-ICD. This was done with the rationale 
that a high level of overexpression may yield a phenotype from which we could 
extrapolate an endogenous function.  Our data for smaller proteins like GFP and Cre 
recombinase were obtained from immunostained brain sections. We therefore needed to 
be able to estimate the extent of overexpression in comparison to the WT. We therefore 
injected rAAV8 expressing ?-ICD into the ventricles of P0 WT pups, followed by a 
“booster” injection at P2 to infect more cells. Twenty days later mice were sacrificed and 
protein lysates were prepared from their forebrains, and probed for the presence of the ?-
ICD.  As can be seen (Figure 17 A), in 3/3 cases, this resulted in significantly higher ?-
ICD levels compared to uninjected controls.  The viral plasmid that we used contained a 
c-Myc tagged version of the ?-ICD, followed by an internal ribosomal entry site (IRES) 
and a Venus encoding cassette (Stefan Bonn, doctoral thesis, 2007).  Western blots 
against the c-Myc tag and against the Venus protein clearly show that most of the ?-ICD 
we detected in the injected brain lysates originated from our construct. In addition, levels 
of the full-length ?-Pcdh were similar in injected and control animals (Figure 17 A). We 
were also interested to see if we could pull down the overexpressed ?-ICD. We performed 
immunoprecipitation on injected brain lysates as described above. As shown in Figure 17 
B, the overexpressed ?-ICD could be efficiently immunoprecipitated. Since we could  
demonstrate that we can effectively overexpress the ?-ICD in high levels and retrieve it 
under native conditions, we were ready to proceed to the next step, measuring 
physiological effects of ?-ICD overexpression in the cortex. 
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Figure 17. Efficient overexpression and immunoprecipitation of ?-ICD in mouse forebrain after 
ventricular injections 
A. Comparison of the immunoreactive band after WB of brain lysates from newborn mice injected in the 
ventricles with rAAV8.Syn.c-Myc-?-ICD IRES.Venus (P0 and booster P2) and from non-injected litter 
mate controls. Western blot analysis was performed against ?-Pcdhs (top panel), GFP (second from top), c-
Myc (second from bottom), and p38 MAPK as loading control (bottom). While full-length ?-Pcdh levels 
were unchanged in injected mice (indicated by arrow, top), the small molecular weight ?-ICD was highly 
overexpressed (indicated by arrow, bottom). B. Western blot after immunoprecipitation of overexpressed ?-
ICD; input, supernatant (Sup), beads and IP fractions are shown. Signal for the full length ?-Pcdh (top 
arrow) can be seen in all fractions of injected (left panel) and non injected control mice (right panel). 
Highest intensity is seen in the IP fraction.  ?-ICD signal (bottom arrow) is higher in injected mice (left 
panel) than in the non injected control (right panel). Highest intensity is seen in the IP fraction of both 
mice. In order to avoid over-exposure of the signal from the concentrated IP fraction, 50% total protein 
amounts (compared to A) were loaded. (exposure less than 30 seconds). 
 
3.2.8 Physiological effects of ?-ICD overexpression in principal cortical neurons 
We were interested in observing the effects of ?-ICD overexpression on synaptic 
properties of virally transduced cells in the cortex, a region of the brain that is most 
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associated with higher cognitive functions, and displays intricate interconnectivity and 
plasticity. 
We injected P0 WT mice with rAAV8 expressing ?-ICD. The human synapsin promoter 
in this vector restricts expression to principal neurons (Kugler et al., 2003). We set out to 
measure the effect of this overexpression on the post-synaptic compartment in these 
neurons. The most straightforward method to do this is to record miniature synaptic 
currents by inhibiting spontaneous firing with tetrodotoxin (TTX). We performed 
recordings under conditions which enabled us to record both miniature excitatory, and 
inhibitory, post-synaptic currents in voltage clamp configuration (mEPSCs and mIPSCs, 
respectively). Surprisingly, while mEPSC amplitudes were entirely unchanged in neurons 
from virus injected vs. control mice (Figure 18 A,B), mIPSC amplitudes of the same 
neurons were greatly increased (mean values were 11.6 ± 0.71 pA vs. 9.6 ± 0.29 pA, 
N=13 and 12 cells from injected vs. control mice, respectively. P < 0.02, T-test. Figure 
18 C,D). Frequency of mIPSCs was higher in injected mice, though not significant (225 ± 
86.9 vs. 61 ± 27.3 events per minute for injected vs. control mice. P > 0.08, T-test). 
Frequency, however, is very variable and increases in frequency are usually concurrently 
detected with increases in amplitude because of more miniature events that pass above 
detection threshold (7.5 pA). 
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Figure 18. Increased miniature inhibitory post-synaptic currents in ?-ICD overexpressing cells 
A. Sample traces recorded at a -70 mV holding potential of cells from injected (top trace) and control mice 
(bottom trace). Negative deflection in the current trace are individual mEPSCs. Scale bar is 10 pA. B. 
Cumulative histograms of mEPSC amplitude distributions for injected (grey) and control (black) groups 
overlay each other; no difference was detected between the groups. C. Sample traces recorded at a +10 mV 
holding potential from the same cells shown in A (top and middle trace correspond to cells from injected, 
and WT control mice, respectively). Positive deflections of the current trace are individual mIPSCs.  Note 
that mIPSCs are significantly larger in amplitude in the injected group.  The bottom trace is the current 
trace from the same control cell (middle trace), after perfusion of picrotoxin into the recording chamber and 
inhibition of GABA receptors in order to demonstrate that all recorded events are indeed GABA receptor-
mediated currents. Scale bar is 20 pA. D. Cumulative histograms of mIPSC distribution shows a clear 
increase of mIPSC amplitudes in neurons from injected mice vs. controls. 
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This is the first physiological effect mediated by ?-Pcdhs in the adult cortex. The large 
difference in amplitude distribution of the mIPSCs which is a mostly post-synaptic 
property, together with the fact that our viral vector targets exclusively excitatory 
neurons, strongly support a role for the ?-ICD in shaping the inhibitory post-synapse.  
Taken together, these data show that we can overexpress the small molecular weight ?-
ICD protein, well above endogenous levels. We can also immunoprecipitate it and this 
may enable us to study also weaker interactions, for example, between the ?-ICD and 
proteins that bind to it in a transient manner. Furthermore, the overexpression of the ?-
ICD induces a physiological synaptic phenotype, which corroborates the validity of this 
technique for the advancement of ?-Pcdhs research. 
In conclusion, the expression of the ?-ICD using our viral delivery system in neonates 
will hopefully allow us to achieve this overexpression in large regions of the brain, and 
observe physiological, morphological and behavioral phenotypes that may give us 
together with our biochemical findings a window to the function of ?-Pcdhs in brain 
complexity.  
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4. Discussion 
4.1 ?-Pcdh structure and processing suggests a role in signal transduction 
?-Pcdhs are essential for survival since mice lacking the gene locus encoding them (or the 
?-ICD) die shortly after birth (Wang et al., 2002b; Hambsch et al., 2005). Lack of ?-Pcdhs 
has been associated with interneuronal death (Wang et al., 2002b; Weiner et al., 2005), 
but other than that the function of these proteins remains unknown. The ?-Pcdhs have 
variable extracellular domains, and their combinatorial expression in individual cells 
generates variation, resulting in unique Pcdh a “signature” in each cell. In contrast to the 
variability of their extracellular domains, there is only one ?- and one ?- cluster specific 
intracellular domain, the ICD. It was this domain and its functional connotation, which 
interested us most. Various polymorphic extracellular domains, combined with one 
conserved intracellular domain, suggest a role in signal transduction that might be very 
simple, perhaps even binary. A good example for binary signaling, postulated in Chen et 
al. (2008), is neuronal survival vs. apoptosis, mediated via inhibitory binding of ?-Pcdhs 
to PYK2, and thus its seclusion. PYK2 is a kinase whose activity in interneurons of the 
spinal cord leads to cell death. When inhibition of this kinase by the ?-Pcdhs is relieved, 
PYK2 is released and the cell undergoes apoptosis.  
Importantly, ?-Pcdhs undergo presenilin dependent intramembrane proteolysis (PS-IP) to 
release the constant ?-ICD. This is achieved by consecutive proteolysis of two proteases: 
ADAM10 and the ?-Secretase complex (Haas et al., 2005; Hambsch et al., 2005; Reiss et 
al., 2006). Notably, ADAM10 and the ?-Secretase complex are also responsible for 
cleavage of several other important proteins such as Notch, APP, as well as the classic N- 
and E-cadherins (Lammich et al., 1999; Hartmann et al., 2002; Maretzky et al., 2005; 
Reiss et al., 2006).  For these proteins as well as for others (e.g ErbB-4 and SREBP-1), 
the intracellular fragment has been shown to mediate intracellular signaling (Weidemann 
et al., 1989; Brown and Goldstein, 1997; Ni et al., 2001; Marambaud et al., 2003). In the 
case of Notch for instance, which controls cell fate selection throughout development, 
very small amounts of its intracellular domain (Notch-ICD), almost undetectable in vivo, 
have a strong biological effect in the nucleus (Schroeter et al., 1998). The ?-ICD might 
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very well exert signaling mechanisms in the nucleus in a similar manner.  Indeed, the 
level of ?-ICD is also virtually undetectable in the nucleus unless proteasome inhibitors 
are added. Nuclear translocation of the ?-ICD and gene transactivation have been 
demonstrated (Hambsch et al., 2005). Thus, a significant part of my work concentrated on 
the signaling function of this domain. 
 
4.2 ?-Pcdhs and brain complexity: the search for interaction partners 
Considering brain complexity, one of the most interesting questions regards the intricate 
interconnections between myriads of neurons and how they are generated, especially in 
regions related to higher brain functions such as the neocortex. Thus, in our search for ?-
Pcdhs interaction partners we utilized immunoprecipitation of extracts from mouse 
forebrain for mass spectrometry (MS). We chose, newborn (P0) and young adults (P42) 
for our analysis, since we assumed that ?-Pcdhs might be involved in the development of 
neuronal networks, and that different interacting complexes may interact with them 
during different developmental stages. While synaptogenesis peaks in the first two weeks 
after birth to establish the basic brain circuitry, at P42, it is mainly associated with 
plasticity and learning functions (Stern et al., 2001). Unexpectedly, we found similar 
proteins in both age groups, a result suggesting similar signaling functions during early 
and late postnatal development.  
Recently, another search for ?-Pcdhs interacting proteins has been reported (Chen et al., 
2008). These authors performed a yeast two hybrid screen from an adult mouse brain 
cDNA library and were able to identify two tyrosine kinases: PYK2 and FAK as ?-Pcdh 
interactors. They showed that PYK2 activity is abnormally up-regulated in ?-Pcdh 
deficient neurons and that overexpression of PYK2 induces apoptosis in chicken spinal 
cord. Thus, they claim that negative regulation of PYK2 activity by Pcdhs (?- and ?-
Pcdhs) contributes to the survival of subsets of spinal neurons. The connection made 
between ?-Pcdh signaling and apoptosis is, however, not entirely new as this has already 
been shown in the spinal cord of knock-out mice (Weiner et al., 2005).  
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Interestingly, we detected neither PYK2, nor FAK by MS. There are several possible 
reasons for this, probably originating from the different methods employed. Chen et al. 
(2008) preformed a yeast two-hybrid assay, followed by transfection of the interactors 
and verification of their association by immunoprecipitation in HEK293T cell lysates, 
and further functional verification in chicken spinal cord in vivo. The yeast two-hybrid 
system, for several reasons, might have given different results when compared to our 
method. First, it utilizes peptides and not native proteins to fish interacting proteins. 
Second, the yeast two-hybrid system utilizes chimeric proteins, a fusion between a 
transcription factor and a fragment of the investigated protein (bait). The protein fusion 
might change the native conformation of the bait and/or prey (interacting protein) and 
might consequently alter binding properties. Third, the use of yeast as hosts may result in 
misfolding, as well as inappropriate post-translational modifications of the studied 
proteins. Last, some proteins might be toxic for yeast and therefore not be represented in 
the library (Van Criekinge and Beyaert, 1999). Another possible source for variation is 
the origin of the material with which we, and Chen et al. (2008) worked: protein lysates 
and a cDNA clones from library, respectively. Proteins whose endogenous levels are low 
might not be detected in our approach, and proteins which associate with ?-Pcdhs as a 
part of a  complex might not be detected in the yeast two-hybrid approach.  In our study 
we chose immunoprecipitation from brain lysates, analyzed by MS, to identify proteins 
interacting with ?-Pcdhs. This method is very sensitive, accurate and allows the use of the 
original mouse model system (Hale et al., 2000). 
In conclusion, we show that MS analysis yields other protein partners, which might 
unravel a role of ?-Pcdhs in the formation of brain complexity. Our results discussed 
herein support this hypothesis. 
In the following we discuss the nature of ?-Pcdh interacting proteins identified and 
verified by us, considering first the KH domain containing, RNA binding, signal 
transduction associated proteins, Sam68 and SLM-2. 
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4.3 Sam68 and SLM-2: ?-Pcdhs interacting proteins reveal possible functions of ?-
Pcdhs 
Sam68 was originally identified as the major target for Src phosphorylation during 
mitosis (hence the name: Src-associated in mitosis 68 kDa protein) and contains several 
Src Homology domains (SH2 and SH3), as well as a classic KH2 RNA binding domain.  
Its exact function is not clear (Rajan et al., 2008).  SLM-2 (Sam68-like mammalian 
protein 2) is a close homologue of Sam68, which probably participates in similar 
pathways (Di Fruscio et al., 1999). 
A variety of possible biological roles have been proposed for Sam68 including mitosis 
and cell cycle regulation, signal transduction, tumor suppression, regulation of alternative 
splice site selection and even retro-viral transport (Lukong and Richard, 2003). 
Interestingly, Sam68 and SLM-2 (as well as SLM-1) have been shown to localize in 
Sam68/SLM nuclear bodies, called SNBs in cancer cell lines (Chen et al., 1999). 
Sam68 is predominantly nuclear but is phosphorylated in the cytoplasm by both Src and 
ERK, and acts as a transcriptional regulator. This is of interest as Both the Src and ERK 
proteins that interact with Sam68 have been implicated in signal transduction pathways 
involved in neuronal properties such as synaptic plasticity and long-term memory. In fact, 
Src is believed to upregulate the activity of NMDA receptors, critical molecules in 
synaptic plasticity (Kalia et al., 2004; Sweatt, 2004). These proteins, participating in 
major signal transduction pathways related to the cell cycle, also serve as regulators of 
long term plasticity and memory in neurons. For example, inhibition of ERK 
phosphorylation inhibits the formation of long-term taste aversion memory (Berman et 
al., 1998). A function of these pathways in neurons other than their “classic” role in other 
cell types might be possible since, unlike other cell types, neurons very rarely undergo 
cell division (Zhao et al., 2008). 
In this regard, it is important to review the known facts about the function of Sam68 in 
neurons. Sam68 has been shown to bind different sets of RNAs in different cell types 
(Grange et al., 2009), and has been shown to be expressed in the somatodendritic 
compartment of neurons, where it associates with dendritically localized mRNAs, 
probably via its KH2 domain. Very recently, Sam68 was immunoprecipitated from 
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cultured hippocampal neurons and several mRNAs bound to it were identified using 
microarray screening (including the activity-responsive mRNA coding for translation 
elongation factor eEF1A; Grange et al. (2009). Another important finding from this study 
was an interaction between Sam68 and the NMDA receptor. This could potentially 
provide an indirect link between ?-Pcdhs and synaptic plasticity. Furthermore, Sam68 has 
been implicated in the regulation of a set of alternatively spliced exons during 
neurogenesis. Differentiation of primary neuronal progenitor cells from embryonic mouse 
neocortex was shown to be promoted by overexpression of Sam68, and suppressed by its 
loss (Rajan et al., 2008; Chawla et al., 2009). We propose several mechanisms through 
which the interaction between Sam68 and ?-Pcdhs may take place in neurons. 
First, Sam68 may regulate cell-cycle progression downstream to ?-Pcdh signalling, 
similar to spinal cord neurons (though likely not via PYK2). Second, Sam68 may 
propagate a proliferation signal to subsets of neurons during neurogenesis, and thus help 
in the formation of functional neuronal circuits. Since the association of Sam68 with cell-
cycle regulation is currently unclear (Rajan et al., 2008), both options are still a matter for 
speculation. Third, it is tempting to speculate that Sam68 operates in the complex 
alternative splicing of ?-Pcdhs. Thus Sam68 together with the ?-ICD might affect a cell’s 
‘signature’ - its differential display of ?-Pcdhs isoforms on the cell surface. A fourth 
possibility, inherently different from the functions described up to date for the ?-Pcdhs is 
that Sam68 functions downstream of the ?-Pcdhs in forebrain neurons via the Erk and Src 
pathways to activate gene regulation affecting the long term shaping of synapses.  
 
4.4 Other ?-Pcdhs interacting proteins 
Another bona-fide ?-Pcdhs interaction partner is the G-coupled, inward rectifying K+ 
channel, Kir3.1. This is a member of a large family of ion channel proteins which, as 
their name implies, mediated inward potassium currents via a G-protein coupled receptor. 
It is very difficult to assign a specific function to this protein as this family is involved in 
the regulation of various morphogenetic events, such as the proliferation, differentiation 
and survival of neurons and glia cells (Neusch et al., 2003). The absence of other proteins 
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involved with Kir-related pathways by MS analysis, makes is difficult to speculate on the 
physiological implications of the Kir3.1-?-Pcdhs interaction. 
Our analysis also revealed a number of ?-Pcdhs interacting proteins, which we did not yet 
verify by immunoprecipitation, but that may have significance for the function of ?-
Pcdhs. For example, our list of interactors includes a large group of proteins that are 
involved in RNA metabolism. SART3 (squamous cell carcinoma antigen recognized by T 
cells 3), for example, is an RNA binding protein about which little is known, except that 
it is thought to regulate RNA splicing in the nucleus (Harada et al., 2000). Likewise, LSm 
proteins, including LSm3 and LSm8 (which were detected in our analysis) have been 
shown to interact with the spliceosome, including with the U6 snRNA, and SART3 (also 
known as p110; (Licht et al., 2008). In light of the complex alternative splicing which 
underlies the diversity of Pcdhs, and given that the ?-ICD is able to upregulate the 
expression of the ?-Pcdh transcripts (Hambsch et al., 2005), an interesting possibility is 
that the ?-ICD helps to regulate its own splicing via binding to these proteins (LSm and 
SART3). In this respect, we also detected several heterogeneous nuclear 
ribonucleoproteins that contain RRM motifs, known to interact with mRNA and to 
regulate a variety of processes, including splicing (NCBI conserved domain database, 
domain cd00590:RRM). Another possiblity, of course, is that splicing regulation affects 
RNAs, which regulate different developmental aspects of neuronal connectivity. These 
effects would not necessarily be mutually exclusive. 
Other proteins which we have detected as ?-Pcdhs interactors but are not verified yet may 
also have relevance for the biological function of ?-Pcdhs. For example, STUB1 (STIP1 
homology and U-box-containing protein 1, also known as CHIP which has an E3-
ubiquitin ligase activity and targets misfolded chaperone substrates towards proteasomal 
degradation (Wang and DeFranco, 2005), could potentially also regulate ?-ICD levels in a 
similar mechanism. Indeed, for both ?- and ?-ICD, inhibition of the proteasomal pathway 
was shown to cause their accumulation (Hambsch et al., 2005; Bonn et al., 2007). 
Interestingly, a large yeast two-hybrid screen identified an interaction between STUB1 
and Sam68 (Stelzl et al., 2005). STUB1 could be involved in proteasomal degradation of 
Sam68. Further research is needed to clarify the pertinent interactions in forebrain 
neurons. 
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How may we be sure of the validity of the interaction proteins that we did not yet verify? 
One finding that supports our results is the pull-down of several ?- and ?-Pcdh isoforms 
(Bonn et al., 2007). A control that was not done in my work, though, was 
immunoprecipitation from ?-Pcdh knock-out mice. This was because knock-out mice die 
within a few hours after birth, making it necessary to process the brains immediately as 
they are born. We hope to address these issues with further experiments in the future. 
 
4.5 Current models for ?-Pcdhs research 
To date, most research has focused on genetic models, in which ?-Pcdhs were deleted 
globally or conditionally (Wang et al., 2002b; Hambsch et al., 2005; Weiner et al., 2005; 
Lefebvre et al., 2008; Prasad et al., 2008).  As the deletion of ?-Pcdhs resulted in perinatal 
lethality, it was impossible to assess their function in the post-natal cortex.  
Unfortunately, ?-Pcdhs heterozygous mice do not contribute much information. Though 
the remaining level of ?-Pcdh proteins in heterozygotes is about 25% of the wild-type 
(Hambsch et al., 2005), only mild phenotypic effects are seen (a behavioral effect on the 
transfer of categorized information was detected in the heterozygous mice, our own 
unpublished data). Furthermore, there are three Pcdh cluster, the ?-, ?-, and ?-Pcdhs. The 
?- and ?-Pcdhs appear to display very similar extracellular properties, and they show 
similar proteolytic processing and nuclear transport of their ICD (Bonn et al., 2007). The 
ICDs of ?- and ?-Pcdhs, however, are not homologus, which makes it very difficult to 
address the question of functional redundancy. 
We were interested in studying the possible effects of the ?-Pcdhs and especially of the ?-
ICD on synaptogenesis and synaptic plasticity. To study these functions we may have to 
“push” the system by overexpression and/or mutagenesis of the proteins involved in 
intracellular signaling. For in vivo studies of signaling pathways, we needed to develope a 
system which allows overexpression of the ?-ICD, the putative signaling molecule, by 
means of neonatal viral injection in forbrain. This, in combination with our identified ?-
Pcdhs binding partners might be a promising course of action for the elucidation of the 
signal transduction pathways through which ?-Pcdhs exert their biological function. 
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The amount of ?-Pcdh expression is highest in neonates (Frank et al., 2005), a trait which 
is achieved with our viral expression system. Furthermore, this time window is also 
critical for the establishments of synapses, and thus synaptic plasticity (Hooks and Chen, 
2007; Maffei and Turrigiano, 2008).  
 
4.6 Expression of transgenes by virus-mediated gene transfer into neonatal mouse 
brains 
There are several methods to overexpress exogenous gene products in the brain. We 
dismissed classic transgenics for reasons of the time and labor involved, especially since 
we wanted a versatile and rapid system in which we could potentially express different 
candidate binding partners of the ?-Pcdhs, as well as mutants thereof (e.g. in potential 
interaction domains). Only viral gene delivery into newborns would fulfill all these 
requirements. 
Virally mediated gene transfer is a valuable tool for the infection of defined brain regions 
with high spatial and temporal resolution. It allows us to reliably infect neuronal cell 
populations in neonatal mice brain with high a degree of precision. Notably, the use of 
cell type specific promoters allows even more selective targeting of desired neuronal 
populations. For example, the human synapsin core promoter/enhancer element that we 
used, is relatively short (300 bp), and permits efficient transduction of neurons.  
The disproportionately large size of the ventricles in the brains of newborn mice allows 
the injection of a relatively large volume of virus containing solution and thus an efficient 
systemic infection. We have shown that results are reliable and reproducible, expression 
starts at a distinct time point, depending on the promoter as early as 24 hours after 
injection, and in selective neuronal populations, and may last throughout life. Brain 
damage is negligible as we could not detect any tissue damage or necrosis at the site of 
injection even two weeks after injection of the purified viruses.  
Our technique is especially useful in combination with preexisting transgenic mouse 
lines, specifically those with conditional genes surrounded by LoxP elements (“floxed 
alleles”). For example, in the present work, heterozygous  Rosa262lox indicator mice were 
infected after birth with a virus expressing Cre-recombinase in the region and cell type of 
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interest, or upon ventricular injection, in the entire neocortex. The apparent success and 
efficiency of this method should bypass laborious and time consuming matings with 
deleter mouse-lines expressing Cre-recombinase. Most notably, embryonic expression, 
often a problem with transgenics (and obviously a problem for ?-Pcdhs), due to onset of 
expression during early development, can be avoided with this method. Furthermore, a 
reporter can be combined into this system: as described here, expression of the GFP 
reporter protein is detectable 24 hours after injection. Due to the relatively small 
molecular weight of the Cre-recombinase, and of the ?-ICD, even rAAVs which have a 
relatively small genome (about 6kb, Grimm et al., 1998), can be additionally equipped 
with a fluorescent marker protein. This would allow for fast and easy visual inspection of 
the targeted region, both in tissue slices and, with the advent of new microscopic 
techniques, in whole organ preparations or even ‘in vivo’.   
 
4.7 Physiological phenotypes detected using neonatal overexpression of ?-ICD in 
forebrain; future prospects for ?-Pcdhs research 
Using our viral transduction system in neonates, we attempted first to overexpress the 
entire ?-Pcdh A1. Unfortunately, our results proved unsatisfactory; only a low level of 
expression was detected. This was probably due to the large size of the coding sequence 
and limits in packaging size of rAAV, as we successfully overexpressed the shorter ?-
ICD fragment, much above endogenous levels. As a first step we measured physiological 
effects after ?-ICD overexpression in pyramidal neurons by recording synaptic currents. 
Preliminary results demonstrate that miniature inhibitory post synaptic currents (mIPSCs) 
were greatly increased in amplitude in ?-ICD infected neurons. This novel finding is 
specific for the inhibitory post-synaptic compartment, since excitatory miniature synaptic 
currents (mEPSCs) in the very same cells were not affected. This provides a tool for 
further investigation of the functions of ?-Pcdhs and their interaction partners. Our results 
afford a phenotypic “handle” on which to base future research. 
Previous studies on the effects of ?-Pcdhs on synaptic transmission have yielded 
controversial results and were, in any event limited to interneurons (in the spinal cord and 
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in the retina, (Weiner et al., 2005; Lefebvre et al., 2008). However, no physiological 
results have been reported to date for pyramidal neurons in the cortex. 
Our data revealed a variety of novel interaction partners for ?-Pcdhs, at least one of 
which, Sam68, actually binds dendritic mRNAs (Grange et al., 2009). Unfortunately, 
very little work has been performed with Sam68 in primary neurons or in vivo, and most 
of the literature reports on its role in cancer. One of our future challenges would be to 
examine the way the various putative ?-Pcdhs interaction partners interact with the 
inhibitory post-synapse, by expression of these proteins and mutants thereof, and 
measuring its effects on mIPSCs. Another important question, which may be raised, is 
does the overexpression of the ?-ICD act to inhibit the function of the endogenous ?-
Pcdhs by sequestering endogenous binding partners, or does it act as a constitutively 
active ?-Pcdh? We hope to answer this question by comparing the phenotype of targeted 
?-Pcdh deletion in the conditional ?-Pcdh2lox mouse line (Hambsch et al., 2005) by means 
of neonatal Cre recombinase expressing virus injection, together with that of the ?-ICD 
overexpression. 
In conclusion, using biochemical methods, and a specialized viral vector delivery system, 
we present previously unknown interaction candidates for the ?-Pcdhs, as well as novel 
physiological findings. This study details ongoing work aimed at deciphering the function 
and mechanism of ?-Pcdhs intracellular signaling in the brain. We hope to shed light on 
the signal transduction pathways which connect the formation of brain circuitry with the 
genetic programming in the brain. 
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5. Abbreviations 
CB:  Cerebellum 
CNS:  Central Nervous System 
DDW:  Double Distilled Water 
EC:  Extracellular Cadherin 
ERK:  Extracellular Regulated Kinase 
FC:  Frontal Cortex 
GFP:  Green Fluorescent Protein 
HPc:  Hippocampus 
ICD:  Intracellular Constant Domain 
IP:  Immunoprecipitation 
IRES:  Internal Ribosomal Entry Site 
KO:  Knock-Out 
mE/IPSCs: Miniature Excitatory/Inhibitory Post-Synaptic Currents 
MS:  Mass Spectrometry 
NLS:  Nuclear Localization Signal 
NMDA: N-Methyl D-Aspartic Acid 
OB:  Olfactory Bulb 
Pcdh:  Protocadherins 
PS-IP:  Presenilin Dependent Intramembrane Proteolysis 
rAAV:  Recombinant Adeno-Associated Virus 
Sam68: Src Associated in Mitosis, 68 kDa Protein 
SLM-2: Sam68 Like Mammalian Protein 2 
SNPs:  Single Nucleotide Polymorphism 
Sup:  Supernatant 
TTX:  Tetrodotoxin 
Ven:  Ventricles 
WB:  Western Blot 
WT:  Wild-Type 
X-linked: Cross linked 
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